Algorithms by OpenMedicineLatest published algorithms by OpenMedicinehttps://myopenmedicine.com/algorithmsMetastatic HR+ Breast CancerBiomarker-driven treatment pathway for advanced HR-positive/HER2-negative metastatic breast cancer, prioritizing endocrine therapy with CDK4/6 inhibition and adapting based on timing of relapse and molecular alterations. Subsequent therapy selection is guided by actionable mutations (e.g., ESR1, PIK3CA, AKT/PTEN, BRCA), enabling targeted treatments such as SERDs, PI3K/AKT inhibitors, and PARP inhibitors.

]]>https://myopenmedicine.com/algorithms/metastatic-hr-breast-cancer/9F9983A70E9511F19387766E2280A932https://myopenmedicine.com/algorithms/metastatic-hr-breast-cancer/9F9983A70E9511F19387766E2280A932Thu, 23 Jul 2026 03:06:34 GMTBreast cancer, Inavolisib, Palbociclib, Fulvestrant, Abemaciclib, Ribociclib, Elacestrant, Imlunestrant, Alpelisib, Capivasertib, Olaparib, Talazoparib, Everolimus, Exemestane, Trastuzumab deruxtecan, Sacituzumab govitecan, INAVO120, EMERALD, SOLAR-1, CAPItello-291, BOLERO-2, DESTINY-Breast06, TROPiCS-02, TROPION-Breast01, Estrogen receptor, Progesterone receptor, HER2, PIK3CA, ESR1, BRCA1, BRCA2, AKT1, PTEN, HER2-low, ctDNA, IHC, Metastatic tissue biopsy, Endocrine therapy, ChemotherapyMetastatic Prostate CancerMetastatic prostate cancer treatment algorithm outlining evidence-based therapy pathways between Hormone-Sensitive and Castration-Resistant prostate cancer. Reference diagram.

]]>https://myopenmedicine.com/algorithms/metastatic-prostate-cancer/09C9BBB0E04B11F0991F766E2280A932https://myopenmedicine.com/algorithms/metastatic-prostate-cancer/09C9BBB0E04B11F0991F766E2280A932Tue, 23 Dec 2025 22:02:13 GMTAxel MerseburgerMedical Oncology, Genitourinary Oncology, Prostate cancer, Metastatic prostate cancer, Castration-resistant prostate cancer, Hormone-sensitive prostate cancer, Abiraterone, Enzalutamide, Darolutamide, Apalutamide, Docetaxel, Olaparib, Rucaparib, Cabazitaxel, Androgen deprivation therapy, Maintenance therapy, Immunotherapy, Radiation therapy, Prostate, PSMA, Lutetium-177 PSMA, Radium-223Treatment of Myeloma: First RelapseUpdated 2025 treatment algorithm for multiple myeloma patients with first relapse. Based on recent data presented at ASH 2025 about the MajesTEC-3 trial which showed higher PFS for patients using the tec-dara combination.

Consider salvage ASCT as alternative in patients eligible for ASCT who have not had transplant before; Consider 2°d auto SCT if eligible and had >36 months response duration with maintenance to first ASCT

]]>https://myopenmedicine.com/algorithms/treatment-of-myeloma-first-relapse/792FD657DC5E11F0991F766E2280A932https://myopenmedicine.com/algorithms/treatment-of-myeloma-first-relapse/792FD657DC5E11F0991F766E2280A932Thu, 23 Jul 2026 03:07:29 GMTVincent RajkumarHematology, Hematologic oncology, multiple myeloma, ciltacabtagene autoleucel, daratumumab, lenalidomide, elotuzumab, MajesTEC-3, CD38, BCMA, CAR T-cell therapy, bispecific antibody therapy, autologous stem cell transplantation, progression-free survivalHigh-Risk Localized/Locally Advanced Prostate Cancer: Perioperative Systemic Therapy With Radical ProstatectomyThe clinical objective of this algorithm is to support patient selection and postoperative management decisions for selected patients with high-risk localized or locally advanced prostate cancer who are being considered for radical prostatectomy with perioperative systemic therapy. The algorithm incorporates emerging data from the PROTEUS trial while avoiding extrapolation beyond the currently available evidence.

]]>https://myopenmedicine.com/algorithms/high-risk-localized-locally-advanced-prostate-cancer-perioperative-systemic-therapy-with-radical-prostatectomy/DDBBB788556911F1AA64766E2280A932https://myopenmedicine.com/algorithms/high-risk-localized-locally-advanced-prostate-cancer-perioperative-systemic-therapy-with-radical-prostatectomy/DDBBB788556911F1AA64766E2280A932Fri, 24 Jul 2026 00:36:43 GMTNeal ShoreFred SaadNatalia GandurAxel MerseburgerUrology, Urologic Oncology, Prostate Cancer, Metastatic Prostate Cancer, mPCa, Androgen Deprivation Therapy, Abiraterone, Apalutamide, PROTEUS, Pelvic Lymph Node, Prostate-Specific Antigen, Magnetic Resonance Imaging, Prostate-Specific Membrane Antigen PET, PSMA PET, Computed Tomography, Bone Scan, Conventional Imaging, Radical Prostatectomy, Pelvic Lymph Node Dissection, PLND, Extended Pelvic Lymph Node Dissection, ePLND, Radiation Therapy, Salvage Radiation Therapy, Salvage RT, Adjuvant Radiation Therapy, Adjuvant RT, Observation, Surveillance, PSA Surveillance, Grade Group, Eastern Cooperative Oncology Group Performance Status, ECOG, Clinical Tumor Stage, Clinical Nodal Stage, Pathology, Staging, Restaging, Toxicity, Androgen Receptor Pathway Inhibitor, ARPI, Perioperative Systemic Therapy, Definitive Radiation Therapy, Salvage TherapyNewly Diagnosed MyelomaTreatment algorithm for newly diagnosed myeloma patients.  Dr. Rajkumar is a contributing editor to the International Myeloma Foundation (https://www.myeloma.org/frontline-treatment-options).

]]>https://myopenmedicine.com/algorithms/newly-diagnosed-myeloma/C21FB97ADD2611F0991F766E2280A932https://myopenmedicine.com/algorithms/newly-diagnosed-myeloma/C21FB97ADD2611F0991F766E2280A932Thu, 23 Jul 2026 03:06:21 GMTVincent RajkumarMultiple myeloma, NDMM, Daratumumab, Isatuximab, Lenalidomide, Bortezomib, del(17p), TP53 mutation, 1p deletion, t(4;14), t(14;16), t(14;20), 1q gain, MRD, Complete blood count, Autologous stem cell transplant, Stem cell collection, Induction therapy, Maintenance therapy, Diarrhea, Fatigue, Rash, Neuropathy, Infection, Chromosome 17p, Chromosome 1p, Chromosome 1qTALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPCThe algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy selection. The main uncertainty is the role of talazoparib + enzalutamide + ADT specifically in the mCSPC setting, which depends on maturation of TALAPRO-3 results and local regulatory/guideline adoption. Monitoring and progression reassessment steps reflect standard oncology care pathways.

]]>https://myopenmedicine.com/algorithms/talapro-3-talazoparib-enzalutamide-adt-in-hrr-altered-mcspc/89631BFC6F4B11F1AD30766E2280A932https://myopenmedicine.com/algorithms/talapro-3-talazoparib-enzalutamide-adt-in-hrr-altered-mcspc/89631BFC6F4B11F1AD30766E2280A932Thu, 23 Jul 2026 03:06:40 GMTNeeraj AgarwalNatalia GandurProstate cancer, Metastatic castration-sensitive prostate cancer, Metastatic castration-resistant prostate cancer, Talazoparib, Enzalutamide, TALAPRO-3, Androgen deprivation therapy, Homologous recombination repair alteration, ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C, Prostate-specific antigen, Germline testing, Somatic testing, Cell-free DNA testing, Tissue-based testing, Complete blood count, Vitamin B12 test, Folate test, Iron studies, Testosterone level, Imaging, Hemoglobin, Fatigue, Nausea, Dizziness, Falls, Anemia, Neutropenia, Thrombocytopenia, Transfusion, Dose reduction, Supportive careSecond-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC)The algorithm is broadly aligned with current practice for previously treated metastatic PDAC in emphasizing performance status assessment, clinical trial enrollment, molecular profiling, and use of evidence-based cytotoxic options (notably nal-IRI + 5-FU/LV after gemcitabine-based therapy). The standard-therapy branches are consistent with major guidelines, though optimal sequencing between gemcitabine/nab-paclitaxel and 5-FU–based regimens after first line is individualized and supported mainly by guideline consensus and non-randomized comparative data. The daraxonrasib (RASolute-302) pathway is explicitly noted as pending peer-reviewed publication, and should be considered investigational until full data and guideline incorporation.

]]>https://myopenmedicine.com/algorithms/second-line-previously-treated-metastatic-pancreatic-cancer-mpdac/A5E452D5552911F1AA64766E2280A932https://myopenmedicine.com/algorithms/second-line-previously-treated-metastatic-pancreatic-cancer-mpdac/A5E452D5552911F1AA64766E2280A932Thu, 23 Jul 2026 03:06:19 GMTMike J. PishvaianAllyson OceanNicholas HornsteinMetastatic pancreatic adenocarcinoma, Metastatic pancreatic cancer, Pancreatic ductal adenocarcinoma, mPDAC, Daraxonrasib, Gemcitabine, Irinotecan liposome injection, 5-fluorouracil, 5-FU, Leucovorin, Nab-paclitaxel, RASolute-302, Pancreas, KRAS, NRAS, HRAS, Next-generation sequencing, Circulating tumor DNA, ctDNA, Molecular profiling, Radiographic confirmation, Performance status assessment, ECOG performance status, Disease progression, Best supportive care, Cytotoxic chemotherapy, FOLFIRINOX, Systemic therapy, Palliative careNewly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment SelectionThis algorithm is broadly aligned with contemporary adult non-APL AML practice: urgent exclusion of APL and stabilization, early comprehensive cytogenetic/molecular profiling, fitness-based selection of intensive vs lower-intensity therapy, and biomarker-directed induction choices (CBF+GO, FLT3 inhibitor with 7+3, CPX-351 for AML-MR/therapy-related, HMA+venetoclax for unfit). It appropriately highlights TP53-altered AML as very-high risk with trial prioritization and uncertain benefit from intensive chemotherapy. Lower-intensity IDH1-targeted therapy (azacitidine+ivosidenib) is consistent with pivotal randomized evidence and guideline use. Some elements are evolving/less standardized (optimal lower-intensity FLT3 or IDH2-targeted combinations; broad “favorable/intermediate-risk” use of HMA+venetoclax regardless of age/fitness).

]]>https://myopenmedicine.com/algorithms/newly-diagnosed-non-apl-acute-myeloid-leukemia-initial-treatment-selection/D2B5A53B74DD11F1AD30766E2280A932https://myopenmedicine.com/algorithms/newly-diagnosed-non-apl-acute-myeloid-leukemia-initial-treatment-selection/D2B5A53B74DD11F1AD30766E2280A932Thu, 23 Jul 2026 03:06:59 GMTTalha BadarHematology, Hematologic oncology, Acute myeloid leukemia, AML, Acute promyelocytic leukemia, APL, Myelodysplastic syndrome, Disseminated intravascular coagulation, Sepsis, All-trans retinoic acid, ATRA, Gemtuzumab ozogamicin, Midostaurin, Quizartinib, CPX-351, Azacitidine, Venetoclax, Ivosidenib, Enasidenib, Bone marrow, Core-binding factor, CD33, FLT3-ITD, FLT3-TKD, NPM1, CEBPA, IDH1, IDH2, TP53, 17p deletion, Uric acid, Lactate dehydrogenase, Phosphorus, Potassium, Calcium, Bone marrow aspirate, Bone marrow biopsy, Complete blood count, Comprehensive metabolic panel, Coagulation studies, Karyotype, Cytogenetics, Fluorescence in situ hybridization, Minimal residual disease, Cultures, Transfusion, Allogeneic hematopoietic stem cell transplantation, Leukostasis, Hyperleukocytosis, Bleeding, Anemia, Thrombocytopenia, Induction therapy, Intensive chemotherapy, Supportive care, Consolidation therapySecond relapse multiple myelomaTreatment algorithm for second relapse multiple myeloma. For BCMA sensitive, approach is similar to first relapse. For second relapse belantamab combinations provide an additional option. Consider salvage ASCT as alternative in patients eligible for ASCT who have not had transplant before; Consider 2°d auto SCT if eligible and had >36 months response duration with maintenance to first ASCT.

Active drugs in multiple myeloma reference.

mSMART 4.0 risk stratification of active multiple myeloma.


]]>https://myopenmedicine.com/algorithms/second-relapse-multiple-myeloma/C178AD8F02BA11F1842F766E2280A932https://myopenmedicine.com/algorithms/second-relapse-multiple-myeloma/C178AD8F02BA11F1842F766E2280A932Thu, 23 Jul 2026 03:06:22 GMTVincent RajkumarRetroperitoneal Well-differentiated (WD) and dedifferentiated (DD) liposarcomaThe algorithm is broadly aligned with contemporary WD/DDLPS practice: expert sarcoma-center workup with MDM2 confirmation, surgery as the cornerstone for localized disease, and anthracycline-based systemic therapy as standard first-line for advanced DDLPS. It appropriately distinguishes WD-only disease (generally surgery-focused) from DDLPS (higher metastatic risk and greater role for systemic therapy). The metastatic pathway reflects commonly used later-line agents (eribulin, trabectedin, gemcitabine-based regimens), but the abemaciclib strategy and growth-rate-based selection remain evolving and not yet uniform standard-of-care.

]]>https://myopenmedicine.com/algorithms/retroperitoneal-well-differentiated-wd-and-dedifferentiated-dd-liposarcoma/44C85D885F7511F186E5766E2280A932https://myopenmedicine.com/algorithms/retroperitoneal-well-differentiated-wd-and-dedifferentiated-dd-liposarcoma/44C85D885F7511F186E5766E2280A932Wed, 3 Jun 2026 17:54:29 GMTMichael WagnerLiposarcoma, Soft tissue sarcoma, Abemaciclib, Doxorubicin, Trabectedin, Eribulin, Gemcitabine, Docetaxel, Dacarbazine, Palbociclib, STRASS, SARC041, Retroperitoneum, Abdomen, Pelvis, Chest, MDM2, CDK4, MRI, Computed tomography, MDM2 testing, Core needle biopsy, Multidisciplinary tumor board review, Surgery, Radiation therapy, Chemotherapy, Rapid growth, Slow growthRET fusion–positive NSCLC: evolving adjuvant and metastatic targeted therapiesThe metastatic portion is broadly aligned with current standards: comprehensive RET fusion testing at diagnosis and first-line selective RET inhibition (selpercatinib or pralsetinib) is guideline-concordant and supported by phase 3 and robust phase 1/2 evidence. The post-progression approach (re-biopsy/ctDNA, CNS assessment, local therapy for oligoprogression, and platinum/pemetrexed chemotherapy) reflects common contemporary practice but is supported more by consensus and extrapolation than RET-specific randomized data. The adjuvant selpercatinib component is plausible but remains evolving and should be treated as investigational/pending until full phase 3 data and regulatory/guideline integration are available.

]]>https://myopenmedicine.com/algorithms/ret-fusion-positive-nsclc-evolving-adjuvant-and-metastatic-targeted-therapies/982AAC97562811F1AA64766E2280A932https://myopenmedicine.com/algorithms/ret-fusion-positive-nsclc-evolving-adjuvant-and-metastatic-targeted-therapies/982AAC97562811F1AA64766E2280A932Thu, 23 Jul 2026 03:06:35 GMTGilberto LopesNon-small cell lung cancer, Selpercatinib, Pralsetinib, Pemetrexed, Pembrolizumab, LIBRETTO-432, LIBRETTO-431, AcceleRET, Central nervous system, RET fusion, Next-generation sequencing, Plasma next-generation sequencing, Circulating tumor DNA, Biopsy, Surgery, Radiation therapy, Chemotherapy, ImmunotherapyLocally advanced and metastatic Cutaneous Squamous Cell Carcinoma (cSCC)The algorithm is broadly aligned with contemporary management of locally advanced/metastatic cSCC, particularly the prioritization of PD-1 blockade for unresectable or metastatic disease and use of surgery and adjuvant RT for appropriate resectable high-risk cases. Inclusion of neoadjuvant PD-1 for borderline resectable disease reflects an evidence-supported but still evolving area. The adjuvant systemic immunotherapy component is appropriately flagged as emerging, with practice variation depending on guideline updates, approvals, and trial maturation.

]]>https://myopenmedicine.com/algorithms/locally-advanced-and-metastatic-cutaneous-squamous-cell-carcinoma-cscc/DF93957E48A911F194D9766E2280A932https://myopenmedicine.com/algorithms/locally-advanced-and-metastatic-cutaneous-squamous-cell-carcinoma-cscc/DF93957E48A911F194D9766E2280A932Tue, 5 May 2026 17:43:06 GMTOmid HamidCutaneous squamous cell carcinoma, Squamous cell carcinoma, Autoimmune disease, Pneumonitis, Colitis, Hepatitis, Nephritis, Myocarditis, HIV, Cemiplimab, Pembrolizumab, Cosibelimab-ipdl, Corticosteroids, CK-301-101, Skin, Head and neck, Eye, Ear, Nose, Facial nerve, PD-L1, Tumor mutational burden, Circulating tumor DNA, UV mutational signature, Next-generation sequencing, Comprehensive genomic profiling, Imaging, Complete blood count, Comprehensive metabolic panel, Liver enzymes, Creatinine, Thyroid function tests, Mohs surgery, Surgery, Diarrhea, Abdominal pain, Dyspnea, Cough, Rash, Fever, Fatigue, Weakness, Headache, Chest pain, Jaundice, Radiation therapy, Checkpoint inhibitor therapy, PD-1 blockade, EGFR-directed therapy, Chemotherapy, Immunotherapy, Neoadjuvant therapy, Adjuvant therapy, SurveillanceMetastatic Hormone-Sensitive Prostate Cancer: When to Use Doublet vs Triplet Systemic TherapyThis algorithm is designed to guide first-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC), focusing specifically on the decision between ADT + ARPI versus ADT + docetaxel + ARPI. It avoids duplicating a broad metastatic prostate cancer pathway and instead focuses on patient selection for doublet versus triplet systemic therapy.

Broadly aligned with current standard management of mHSPC: treatment intensification beyond ADT alone for most patients, with selection of doublet (ADT+ARPI) versus triplet (ADT+docetaxel+ARPI) based on disease volume/risk, de novo vs metachronous presentation, symptoms/visceral disease, and chemotherapy fitness. The strongest evidence for triplet is in de novo high-volume/high-risk, docetaxel-fit patients (ARASENS; PEACE-1). The emphasis on ADT+ARPI for lower-volume and/or metachronous disease is consistent with major guidelines and multiple pivotal ARPI trials. Prostate radiotherapy for de novo low-volume disease is supported by randomized data, though integration with systemic intensification continues to evolve.

]]>https://myopenmedicine.com/algorithms/metastatic-hormone-sensitive-prostate-cancer-when-to-use-doublet-vs-triplet-systemic-therapy/0B414F2A498A11F194D9766E2280A932https://myopenmedicine.com/algorithms/metastatic-hormone-sensitive-prostate-cancer-when-to-use-doublet-vs-triplet-systemic-therapy/0B414F2A498A11F194D9766E2280A932Fri, 24 Jul 2026 00:31:21 GMTNatalia GandurMedical Oncology, Genitourinary Oncology, Metastatic hormone-sensitive prostate cancer, mHSPC, Prostate cancer, Docetaxel, Abiraterone, Zytiga, Prednisone, Enzalutamide, Xtandi, Apalutamide, Erleada, Darolutamide, Nubeqa, ARASENS, PEACE-1, ECOG performance status, Androgen deprivation therapy, Androgen receptor pathway inhibitor, ARPI, Prostate radiotherapy, Frailty, Prostate, Visceral metastases, Metastatic prostate cancer, mPCaFirst-line Advanced/Metastatic Squamous NSCLC: HARMONi-6 based Treatment SelectionThe algorithm is broadly aligned with current first-line management of advanced/metastatic squamous NSCLC: universal biomarker testing, PD-L1–informed selection, and chemoimmunotherapy as the dominant standard for most patients without actionable drivers. The emphasis on intensified chemoimmunotherapy for PD-L1–negative or high-burden disease is consistent with guideline-based practice and pivotal chemo-IO trials. Positioning ivonescimab + chemotherapy as an “emerging preferred” option is directionally supported by HARMONi-6 (PFS benefit vs tislelizumab + chemo), but its role as a new standard is contingent on regulatory approval, OS/maturity of data, and regional availability.

]]>https://myopenmedicine.com/algorithms/first-line-advanced-metastatic-squamous-nsclc-harmoni-6-based-treatment-selection/F54F439F562F11F1AA64766E2280A932https://myopenmedicine.com/algorithms/first-line-advanced-metastatic-squamous-nsclc-harmoni-6-based-treatment-selection/F54F439F562F11F1AA64766E2280A932Thu, 23 Jul 2026 03:06:47 GMTBen BleibergCharu AggarwalNon-small cell lung cancer, NSCLC, Autoimmune disease, Ivonescimab, Tislelizumab, Pembrolizumab, Carboplatin, Paclitaxel, HARMONi-6, HARMONi-3, Liver, Lymph node, Blood vessel, PD-L1, Molecular profiling, Next-generation sequencing, Plasma testing, Biopsy, Imaging, Maintenance therapy, Induction therapy, Respiratory hemorrhage, Immunotherapy, Chemoimmunotherapy, Chemotherapy, Targeted therapyAdvanced bladder cancerFirst-line treatment for advanced urothelial carcinoma now prioritizes enfortumab vedotin plus pembrolizumab, with alternatives including platinum-based chemotherapy followed by avelumab maintenance or chemo-immunotherapy combinations. Subsequent therapy is guided by prior exposure and biomarkers, incorporating options such as erdafitinib for FGFR-altered disease, HER2-targeted therapy, immunotherapy, or EV if not previously used.

]]>https://myopenmedicine.com/algorithms/advanced-bladder-cancer/757F3F92346911F1A3AE766E2280A932https://myopenmedicine.com/algorithms/advanced-bladder-cancer/757F3F92346911F1A3AE766E2280A932Fri, 24 Jul 2026 00:03:27 GMTMedical Oncology, Genitourinary Oncology, Bladder cancer, Urothelial carcinoma, Enfortumab vedotin, Pembrolizumab, Avelumab, Erdafitinib, Trastuzumab deruxtecan, T-DXd, Nivolumab, Cisplatin, Gemcitabine, Carboplatin, FGFR3 alteration, FGFR alteration, HER2, Maintenance therapy, Platinum-based chemotherapy, Dose-dense MVAC, ddMVACLocalized and metastatic soft tissue sarcomasThe algorithm is broadly consistent with contemporary soft tissue sarcoma practice: surgery with selective radiotherapy for localized disease, and anthracycline-based systemic therapy followed by histology-appropriate later-line options for metastatic disease. Key metastatic options listed (doxorubicin, gemcitabine/docetaxel, trabectedin for LMS/LPS, pazopanib for non-adipocytic STS, eribulin for LPS) align with major guidelines and pivotal trials. However, the localized neoadjuvant chemotherapy and especially neoadjuvant pembrolizumab + RT for UPS are more selective/center-dependent and supported by smaller or evolving evidence.

]]>https://myopenmedicine.com/algorithms/localized-and-metastatic-soft-tissue-sarcomas-nbsp/60C0980655FC11F1AA64766E2280A932https://myopenmedicine.com/algorithms/localized-and-metastatic-soft-tissue-sarcomas-nbsp/60C0980655FC11F1AA64766E2280A932Thu, 23 Jul 2026 03:07:32 GMTMichael WagnerSoft tissue sarcoma, Undifferentiated pleomorphic sarcoma, Leiomyosarcoma, Liposarcoma, Doxorubicin, Ifosfamide, Pembrolizumab, Gemcitabine, Docetaxel, Trabectedin, Pazopanib, Eribulin, Anlotinib, Extremity, Abdomen, Retroperitoneum, Surgery, Neoadjuvant chemotherapy, Systemic therapy, Maintenance therapy, Radiation therapySTK11/KEAP1 Advanced/Metastatic Non-Squamous NSCLCThe algorithm is partially aligned with current metastatic Non-Squamous NSCLC practice in its emphasis on broad molecular testing and guideline-directed targeted therapy when actionable drivers are present, and on chemo-immunotherapy as the backbone for most patients. However, it elevates tremelimumab+durvalumab+platinum (POSEIDON) as a preferred approach specifically for STK11/KEAP1-altered disease, which is not a universally guideline-endorsed biomarker-directed standard and rests largely on subgroup/biomarker analyses rather than dedicated prospective biomarker-stratified trials. The ivonescimab-based intensification approach remains investigational/region-dependent and should generally be framed as clinical-trial or where approved/available.

]]>https://myopenmedicine.com/algorithms/stk11-keap1-advanced-metastatic-non-squamous-nsclc/BE4DB1715AE111F186E5766E2280A932https://myopenmedicine.com/algorithms/stk11-keap1-advanced-metastatic-non-squamous-nsclc/BE4DB1715AE111F186E5766E2280A932Thu, 23 Jul 2026 03:06:24 GMTCharu AggarwalBen BleibergOncology, Thoracic oncology, Non-small cell lung cancer, NSCLC, POSEIDON, CheckMate 9LA, KEYNOTE-189, tremelimumab, durvalumab, nivolumab, Opdivo, ipilimumab, Yervoy, pembrolizumab, pemetrexed, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, ivonescimab, STK11, KEAP1, PD-L1, EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF V600E, MET exon 14 skipping, RET rearrangement, NTRK fusion, Next-generation sequencing, targeted therapy, chemoimmunotherapy, platinum-doublet chemotherapy, induction therapy, maintenance therapy, colitis, dermatitis, autoimmune disease, organ transplantMetastatic clear cell RCC first-line treatment selectionAlgorithm for selection of first-line treatment for patients with metastatic clear cell RCC (mccRCC). The National Comprehensive Cancer Network, European Association of Urology, and European Society of Medical Oncology guidelines recommend alternative approaches. 


axi = axitinib; cabo = cabozantinib; IMDC = International Metastatic RCC DatabaseConsortium; ipi = ipilimumab; lenva = lenvatinib ; Nivo = nivolumab; Pembro = pembrolizumab; RCC = renal cell carcinoma; SBRT = stereotactic body radiotherapy; TKI = tyrosine kinase inhibitor.


Multidisciplinary tumor board discussion should include, but not be limited to, patient preferences and goals, review of images and pathology, need for referral to a high-volume center, potential inclusion in clinical trials, and requirements for additional supportive care interventions.


First and Second-line Treatments in Metastatic Renal Cell Carcinoma, European Urology, Volume 87, Issue 2, 2025, Pages 143-154, https://doi.org/10.1016/j.eururo.2024.10.019.

]]>https://myopenmedicine.com/algorithms/metastatic-clear-cell-rcc-first-line-treatment-selection/82ABCCC3FE1911F0842F766E2280A932https://myopenmedicine.com/algorithms/metastatic-clear-cell-rcc-first-line-treatment-selection/82ABCCC3FE1911F0842F766E2280A932Thu, 23 Jul 2026 03:07:26 GMTToni Choueirirenal cell carcinoma, RCC, axitinib, cabozantinib, ipilimumab, lenvatinib, nivolumab, pembrolizumab, kidney, sarcomatoid features, pathology, imaging, nephrectomy, metastasectomy, tumor board discussion, stereotactic body radiotherapySmoldering Myeloma

Active drugs in multiple myeloma reference.
mSMART 4.0 Risk Stratification of active multiple myeloma.

]]>https://myopenmedicine.com/algorithms/smoldering-myeloma/82B90ECD02B811F1842F766E2280A932https://myopenmedicine.com/algorithms/smoldering-myeloma/82B90ECD02B811F1842F766E2280A932Thu, 23 Jul 2026 03:07:06 GMTVincent RajkumarSmoldering multiple myeloma, Multiple myeloma, Daratumumab, Lenalidomide, CRAB, Plasma cell percentage, Free light chain ratio, Magnetic resonance imaging, Cytogenetics, ObservationToxicity management for duodenal/gastric ulceration after pancreas SBRTHow Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages duodenal/gastric ulceration after pancreas Stereotactic Body Radiation Therapy (SBRT).  Originally posted on YouTube "Managing Toxicity from Radiotherapy to Upper GI Cancers (esophagus, pancreas, liver)" by Dr. Sanford. 

]]>https://myopenmedicine.com/algorithms/toxicity-management-for-duodenal-gastric-ulceration-after-pancreas-sbrt/B5F188010B6A11F19387766E2280A932https://myopenmedicine.com/algorithms/toxicity-management-for-duodenal-gastric-ulceration-after-pancreas-sbrt/B5F188010B6A11F19387766E2280A932Thu, 23 Jul 2026 03:06:29 GMTNina Sanfordduodenum, stomach, pancreas, esophagogastroduodenoscopy, ulcer, anemia, sucralfate, stent placement, epigastric pain, melena, nausea, stereotactic body radiation therapyMuscle-invasive bladder cancer (MIBC)This algorithm outlines a contemporary management approach for muscle-invasive bladder cancer, stratifying patients by cisplatin eligibility and surgical candidacy to guide the use of neoadjuvant chemotherapy, perioperative immunotherapy, or bladder-preserving chemoradiation. It incorporates emerging phase III data supporting perioperative checkpoint inhibitors and antibody–drug conjugates, along with established adjuvant immunotherapy for high-risk residual disease after cystectomy.

]]>https://myopenmedicine.com/algorithms/muscle-invasive-bladder-cancer-mibc/85508EFB346011F1A3AE766E2280A932https://myopenmedicine.com/algorithms/muscle-invasive-bladder-cancer-mibc/85508EFB346011F1A3AE766E2280A932Thu, 23 Jul 2026 03:06:53 GMTMuscle-invasive bladder cancer, Bladder cancer, MIBC, Cisplatin, Gemcitabine, Durvalumab, Nivolumab, Pembrolizumab, Mitomycin, Fluorouracil, NIAGARA, EV-303/304, Bladder, ypT2, Cystectomy, Neoadjuvant chemotherapy, Immunotherapy, Chemoradiation, Radiation therapy, Checkpoint inhibitors, Antibody-drug conjugatesGastric, Gastroesophageal Junction (GEJ) and Esophageal AdenocarcinomaTreatment algorithm for Gastric, Gastroesophageal Junction (GEJ) and Esophageal Adenocarcinoma by Yelena Y. Janjigian, MD, FASCO, Chief, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

]]>https://myopenmedicine.com/algorithms/gastric-gastroesophageal-junction-gej-and-esophageal-adenocarcinoma/EA46013B215C11F1AE8D766E2280A932https://myopenmedicine.com/algorithms/gastric-gastroesophageal-junction-gej-and-esophageal-adenocarcinoma/EA46013B215C11F1AE8D766E2280A932Thu, 23 Jul 2026 03:06:48 GMTYelena Y. JanjigianLocalized and metastatic primary malignant bone sarcomaThe algorithm is broadly aligned with contemporary management of primary malignant bone sarcomas: referral to a sarcoma center, histology-driven pathways, multimodality therapy for osteosarcoma and Ewing sarcoma, and surgery-focused management for conventional chondrosarcoma. Key regimen choices (MAP for osteosarcoma; interval-compressed VDC/IE for Ewing) and emphasis on local control are consistent with major guideline recommendations and pivotal cooperative-group trials. Areas with more limited or evolving evidence include optimal systemic options for relapsed/metastatic osteosarcoma, the role of whole-lung irradiation in metastatic Ewing, and targeted/novel therapies in chondrosarcoma.

]]>https://myopenmedicine.com/algorithms/localized-and-metastatic-primary-malignant-bone-sarcoma/FE6AA352560611F1AA64766E2280A932https://myopenmedicine.com/algorithms/localized-and-metastatic-primary-malignant-bone-sarcoma/FE6AA352560611F1AA64766E2280A932Thu, 23 Jul 2026 03:06:43 GMTMichael WagnerOsteosarcoma, Ewing sarcoma, Chondrosarcoma, Methotrexate, Doxorubicin, Cisplatin, Vincristine, Cyclophosphamide, Ifosfamide, Etoposide, Lung, Skull base, Spine, Biopsy, Magnetic resonance imaging, Computed tomography, Positron emission tomography, Bone scan, Surgical resection, Limb-sparing surgery, Amputation, Pulmonary metastasectomy, Wide en bloc resection, Neoadjuvant chemotherapy, Adjuvant chemotherapy, Radiation therapy, Whole-lung irradiation, Targeted therapy, Multimodality therapy, Local control, Clinical trial, Medical oncology, Orthopedic oncologyTransplant ineligible multiple myelomaTreatment algorithm for transplant ineligible multiple myeloma. For frail patients, anti-CD38 best tolerated drug, other agents can be added as tolerable.

]]>https://myopenmedicine.com/algorithms/transplant-ineligible-multiple-myeloma/07158981EDB911F08C3A766E2280A932https://myopenmedicine.com/algorithms/transplant-ineligible-multiple-myeloma/07158981EDB911F08C3A766E2280A932Thu, 23 Jul 2026 03:07:23 GMTManni MohyuddinHematology and Oncology, Plasma cell disorders, Multiple myeloma, Dexamethasone, Bortezomib, Neuropathy, Minimal residual diseaseOlaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA MutationThe algorithm is broadly aligned with current mCRPC practice in emphasizing PARP inhibition for BRCA1/2-altered disease and continuing therapy until progression/toxicity. The olaparib monotherapy pathway for BRCA-mutated mCRPC after ARPI (and post-taxane) is well supported by pivotal randomized evidence and incorporated into major guidelines. The preference for olaparib+abiraterone in BRCA-mutated mCRPC without prior taxane is directionally consistent with emerging/updated evidence for PARP+AR pathway combinations, but guideline positioning and regulatory labeling vary by region and biomarker definition (BRCA vs broader HRR) and should be verified locally.

]]>https://myopenmedicine.com/algorithms/olaparib-monotherapy-or-in-combination-with-abiraterone-for-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-a-brca-mutation/2388E5544B1011F194D9766E2280A932https://myopenmedicine.com/algorithms/olaparib-monotherapy-or-in-combination-with-abiraterone-for-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-a-brca-mutation/2388E5544B1011F194D9766E2280A932Thu, 23 Jul 2026 03:07:11 GMTNeal ShoreFred SaadRana McKayPARP inhibition, androgen deprivation therapy, supportive care, shared decision-making, metastatic castration-resistant prostate cancer, olaparib, abiraterone, enzalutamide, apalutamide, darolutamide, prednisone, prednisolone, docetaxel, PROpel, PROfound, BRCA1, BRCA2, PSA, imaging, dose modificationsRefractory multiple myelomaRefractory multiple myeloma treatment algorithm. There are many options. But we need more. Good news is more are coming.

Active drugs in multiple myeloma reference. mSMART 4.0 risk stratification of active multiple myeloma.

]]>https://myopenmedicine.com/algorithms/refractory-multiple-myeloma/1A07A8B102BD11F1842F766E2280A932https://myopenmedicine.com/algorithms/refractory-multiple-myeloma/1A07A8B102BD11F1842F766E2280A932Thu, 23 Jul 2026 03:07:18 GMTVincent RajkumarMultiple myeloma, Refractory multiple myeloma, Venetoclax, Talquetamab, Cevostamab, Melphalan, Selinexor, Bendamustine, B-cell maturation antigen, t(11;14), mSMART 4.0 risk stratification, Chimeric antigen receptor T-cell therapy, Bispecific antibody, Alkylator-based regimen, Combination chemotherapy, BCMA bispecific combination, Selinexor-based regimen, Bendamustine-based regimen, VDT-PACE, CVAD, DPACE, VCd, KCd, Intravenous melphalanHR+/HER2- Advanced Breast Cancer

]]>https://myopenmedicine.com/algorithms/hr-her2-advanced-breast-cancer/29B3327B091C11F19387766E2280A932https://myopenmedicine.com/algorithms/hr-her2-advanced-breast-cancer/29B3327B091C11F19387766E2280A932Thu, 23 Jul 2026 03:07:08 GMTIlana SchlamBreast cancer, Palbociclib, Fulvestrant, Inavolisib, Ribociclib, Abemaciclib, Capivasertib, Elacestrant, Imlunestrant, Olaparib, Talazoparib, Alpelisib, Everolimus, Trastuzumab deruxtecan, T-DXd, Datopotamab deruxtecan, Dato-DXd, Sacituzumab govitecan, INAVO120, MONALEESA-2, MONALEESA-3, MONALEESA-7, MONARCH-2, MONARCH-3, PALOMA-2, PALOMA-3, CAPItello-291, EMERALD, EMBER-3, OlympiAD, EMBRACA, SOLAR-1, BYLieve, DESTINY-Breast06, TROPION-Breast01, TROPiCS, DESTINY-Breast04, Hormone receptor, HR+, HER2, HER2-, PIK3CA mutation, PTEN alteration, AKT alteration, ESR1 mutation, Germline BRCA1 mutation, Germline BRCA2 mutation, Immunohistochemistry, IHC 0, Endocrine therapy, Adjuvant endocrine therapy, Aromatase inhibitor, CDK4/6 inhibitor, PARP inhibitor, Chemotherapy, Disease progressionNewly diagnosed metastatic ALK+ NSCLC (ECOG 0–2)As of 2025, NCCN and ASCO list alectinib, brigatinib, ensartinib, and lorlatinib as preferred first-line options for metastatic ALK+ NSCLC. ESMO living guidelines similarly support alectinib, brigatinib and lorlatinib (and ensartinib in some regions) as standard first-line ALK TKIs.

Global 2025 consensus: Use a next-generation ALK TKI (alectinib, brigatinib, ensartinib, or lorlatinib) in all fit metastatic ALK+ patients, not crizotinib (unless it is the only available option).

Main Clinical Trials 
  • Lorlatinib – CROWN 5-year data 5-year PFS still not reached, ~60% progression-free at 5 years vs 9.1 months PFS with crizotinib; best intracranial control seen with any TKI. 
  • Alectinib – ALEX & long-term follow-up Marked PFS and OS advantage vs crizotinib; mature 5-year OS showing durable benefit and excellent CNS activity. In most recent update PFS with alectinib improved by almost 2 years to 34.8 months with a favorable toxicity profile. Secondary endpoint: final overall survival (OS) analysis showed an encouraging median OS of 81.1 months versus 54.2 months in patients receiving alectinib versus crizotinib (hazard ratio 0.78, 95% confidence interval 0.56-1.08) with almost 50% versus 40% of the patients still alive after 7 years, respectively. 
  • Brigatinib & ensartinib – Both improve PFS vs crizotinib and have strong CNS penetration; all four TKIs hold NCCN category 1 preferred status in 2025. (but are less commonly used than alectinib and lorlatinib). 
  • Real-world and comparative data (ASCO/ESMO 2025). Large US claims and registry studies suggest broadly comparable OS for frontline alectinib, brigatinib and lorlatinib; all are superior to crizotinib; lorlatinib often shows numerically best CNS outcomes, but CNS AEs are also more pronounced.
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

]]>https://myopenmedicine.com/algorithms/newly-diagnosed-metastatic-alk-nsclc-ecog-0-2/8AA71A5EDF7511F0991F766E2280A932https://myopenmedicine.com/algorithms/newly-diagnosed-metastatic-alk-nsclc-ecog-0-2/8AA71A5EDF7511F0991F766E2280A932Thu, 23 Jul 2026 03:06:39 GMTGilberto LopesNon-small cell lung cancer, Brain metastases, Alectinib, Brigatinib, Ensartinib, Lorlatinib, Crizotinib, Pemetrexed, Bevacizumab, CROWN, ALEX, Central nervous system, Brain, ALK rearrangement, Next-generation sequencing, ALK test, Fluorescence in situ hybridization, Immunohistochemistry, Brain MRI, Fasting lipid panel, Glucose, Hemoglobin A1c, Liver function tests, Renal function tests, Re-biopsy, Platinum-pemetrexed, Immunotherapy, Local therapy, Local ablative therapy, Palliative radiation therapy, MyalgiasPerioperative Neoadjuvant chemo IO in thoracic solid tumoursResectability Matrix in the ERA of Immunotherapy 

There are several guidelines and the new TNM 9th edition available but none helps to navigate about different options in the Neoadjuvant setting, Adjuvant setting or Perioperative setting. Based on stage options should be objectively compared. There is no consensus reached for some stage features. Resectability decision making is key for patient to be eligible for chemo Immunotherapy. There are guidelines but there is no algorithm to help tumour board or surgeons to define resectability in N2 category or locally advanced cancer (T3 / T4).

]]>https://myopenmedicine.com/algorithms/perioperative-neoadjuvant-chemo-io-in-thoracic-solid-tumours/334E5FB9EFEC11F08C3A766E2280A932https://myopenmedicine.com/algorithms/perioperative-neoadjuvant-chemo-io-in-thoracic-solid-tumours/334E5FB9EFEC11F08C3A766E2280A932Thu, 23 Jul 2026 03:07:05 GMTAndrea Billèlung cancer, locally advanced cancer, thorax, TNM staging, TNM 9th edition, AJCC 8th edition, surgery, salvage surgery, video-assisted thoracoscopic surgery, robotic surgery, neoadjuvant therapy, adjuvant therapy, perioperative therapy, chemotherapy, immunotherapy, radiotherapy, surveillance, residual diseaseTALAPRO-2: Talazoparib + Enzalutamide in HRR-Altered First-Line mCRPCThe algorithm is broadly aligned with contemporary mCRPC management: maintain ADT, perform HRR (germline/somatic) testing early, and consider PARP inhibitor combinations for HRR-altered disease. Placement of talazoparib + enzalutamide in the first-line mCRPC setting is supported by the TALAPRO-2 trial and subsequent regulatory/guideline adoption, with the strongest benefit signal in BRCA1/2 alterations. Key practical considerations (marrow reserve/CBC monitoring, renal dosing, drug interactions) appropriately reflect PARP inhibitor toxicity management.

]]>https://myopenmedicine.com/algorithms/talapro-2-talazoparib-enzalutamide-in-hrr-altered-first-line-mcrpc/9802087B6F5111F1AD30766E2280A932https://myopenmedicine.com/algorithms/talapro-2-talazoparib-enzalutamide-in-hrr-altered-first-line-mcrpc/9802087B6F5111F1AD30766E2280A932Thu, 23 Jul 2026 03:06:36 GMTNatalia GandurNeeraj AgarwalMetastatic castration-resistant prostate cancer, Metastatic castration-sensitive prostate cancer, Prostate cancer, Anemia, Neutropenia, Thrombocytopenia, Myelodysplastic syndrome, Acute myeloid leukemia, Talazoparib, Enzalutamide, Abiraterone, Apalutamide, Darolutamide, Docetaxel, TALAPRO-2, Bone marrow, Homologous recombination repair, ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C, Circulating tumor DNA, Castrate testosterone level, Prostate-specific antigen, Microsatellite instability, Mismatch repair, Tumor mutational burden, Germline testing, Tissue-based tumor testing, Complete blood count, Platelet count, Hemoglobin, Liver tests, Renal function, PSMA PET, Bilateral orchiectomy, Transfusion, Pain, Dizziness, Fatigue, Nausea, Appetite loss, Bleeding, Seizure, Androgen deprivation therapy, Radiotherapy, Radioligand therapyNon-muscle-invasive bladder cancer (NMIBC)Risk-stratified management of NMIBC begins with TURBT, followed by surveillance for low-risk disease and intravesical therapy (BCG preferred) for intermediate- and high-risk tumors. Patients with BCG-unresponsive disease may receive bladder-preserving options such as nadofaragene firadenovec, pembrolizumab, or nogapendekin alfa inbakicept, with radical cystectomy remaining the definitive treatment.

]]>https://myopenmedicine.com/algorithms/non-muscle-invasive-bladder-cancer-nmibc/2256527F344B11F1A3AE766E2280A932https://myopenmedicine.com/algorithms/non-muscle-invasive-bladder-cancer-nmibc/2256527F344B11F1A3AE766E2280A932Thu, 23 Jul 2026 03:07:13 GMTnon-muscle-invasive bladder cancer, carcinoma in situ, BCG-unresponsive disease, Bacillus Calmette-Guérin, nadofaragene firadenovec-vncg, pembrolizumab, nogapendekin alfa inbakicept, cystoscopy, transurethral resection of bladder tumor, radical cystectomy, intravesical therapy, surveillanceMultiply relapsed (triple-refractory) multiple myeloma off trialOff trial treatment algorithm for triple-refractory multiple myeloma off trial.

* Do not delay bispecifics just because you think CAR-T has to be given first (or even collected). Many are harmed due to that belief.

]]>https://myopenmedicine.com/algorithms/multiply-relapsed-triple-refractory-multiple-myeloma-off-trial/210A8BBFEDB811F08C3A766E2280A932https://myopenmedicine.com/algorithms/multiply-relapsed-triple-refractory-multiple-myeloma-off-trial/210A8BBFEDB811F08C3A766E2280A932Thu, 23 Jul 2026 03:07:04 GMTManni Mohyuddinmultiple myeloma, bispecific antibody therapy, CAR T-cell therapy, B-cell maturation antigen, B-cell maturation antigen, G protein-coupled receptor class C group 5 member D, bridging therapy, chemotherapy, cell collection, Talquetamab, ciltacabtagene autoleucelToxicity management for acute radiation esophagitisHow Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages acute radiation esophagitis after radiation therapy (RT) and stereotactic body radiation therapy (SBRT). Originally posted on YouTube "Managing Toxicity from Radiotherapy to Upper GI Cancers (esophagus, pancreas, liver)" by Dr. Sanford. 

]]>https://myopenmedicine.com/algorithms/toxicity-management-for-acute-radiation-esophagitis/1DD6CF0D0B6711F19387766E2280A932https://myopenmedicine.com/algorithms/toxicity-management-for-acute-radiation-esophagitis/1DD6CF0D0B6711F19387766E2280A932Thu, 23 Jul 2026 03:07:15 GMTNina Sanfordradiation esophagitis, pantoprazole, sucralfate, prochlorperazine, radiation therapy, stereotactic body radiation therapy, dysphagia, odynophagia, retrosternal pain, nausea, vomiting, ulcer, fistulaToxicity management for esophageal strictureHow Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages esophageal stricture after radiation therapy (RT). Originally posted on YouTube "Managing Toxicity from Radiotherapy to Upper GI Cancers (esophagus, pancreas, liver)" by Dr. Sanford. 

]]>https://myopenmedicine.com/algorithms/toxicity-management-for-esophageal-stricture/1DB15ACF0B6911F19387766E2280A932https://myopenmedicine.com/algorithms/toxicity-management-for-esophageal-stricture/1DB15ACF0B6911F19387766E2280A932Thu, 23 Jul 2026 03:07:16 GMTNina SanfordEsophageal stricture, Esophagus, Dysphagia, Endoscopy, Biopsy, Dilation, Stent placement, Radiation therapyStage I, II and III Small Cell Lung Cancer (SCLC)Limited-stage Small Cell Lung Cancer treatment with curative intent.

]]>https://myopenmedicine.com/algorithms/stage-i-ii-and-iii-small-cell-lung-cancer-sclc/BA8D6811379511F1A3AE766E2280A932https://myopenmedicine.com/algorithms/stage-i-ii-and-iii-small-cell-lung-cancer-sclc/BA8D6811379511F1A3AE766E2280A932Thu, 23 Jul 2026 03:06:26 GMTSmall cell lung cancer, SCLC, Non-small cell lung cancer, NSCLC, Brain metastases, Cisplatin, Etoposide, Carboplatin, Mediastinum, Thorax, Brain, Mediastinal staging, Surgical resection, Prophylactic cranial irradiation, Chemotherapy, Thoracic radiotherapy, Chemoradiotherapy, Frailty, Growth factor supportToxicity management for radiation-associated nausea and vomitingHow Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages acute radiation associated nausea and vomiting. Originally posted on YouTube "Managing Toxicity from Radiotherapy to Upper GI Cancers (esophagus, pancreas, liver)" by Dr. Sanford. 

]]>https://myopenmedicine.com/algorithms/toxicity-management-for-radiation-associated-nausea-and-vomiting/189F90E30B6C11F19387766E2280A932https://myopenmedicine.com/algorithms/toxicity-management-for-radiation-associated-nausea-and-vomiting/189F90E30B6C11F19387766E2280A932Thu, 23 Jul 2026 03:07:19 GMTNina Sanfordnausea, vomiting, ondansetron, Zofran, dexamethasone, olanzapine, metoclopramide, Reglan, lorazepam, Ativan, prochlorperazine, Compazine, senna, docusate, esophagus, pancreas, liver, endoscopy, radiotherapy, stereotactic body radiation therapy, whole liver radiation therapy, hunger, bleeding, pain, constipation, headache, sedation, postprandial fullness, early satiety, bloating, bowel regimenMetastatic Colorectal Cancer: Biomarker-Driven Treatment Selection, Maintenance, and SequencingThis algorithm is broadly aligned with contemporary standards for metastatic colorectal cancer, emphasizing up-front molecular profiling (MSI/MMR, extended RAS, BRAF, sidedness, HER2/rare targets), intent stratification (resectable/conversion/unresectable), and evidence-based first-line selection including immunotherapy for MSI-H/dMMR and biologic selection by RAS/BRAF and sidedness. The maintenance concepts (fluoropyrimidine + bevacizumab after oxaliplatin-based induction; fluoropyrimidine + anti-EGFR after anti-EGFR induction) are supported by key trials. Sequencing beyond first-line is referenced at a high level but would require a dedicated pathway to remain guideline-concordant across multiple biomarker subgroups and rapidly evolving approvals.

]]>https://myopenmedicine.com/algorithms/metastatic-colorectal-cancer-biomarker-driven-treatment-selection-maintenance-and-sequencing/C6388DAB822211F19EE0766E2280A932https://myopenmedicine.com/algorithms/metastatic-colorectal-cancer-biomarker-driven-treatment-selection-maintenance-and-sequencing/C6388DAB822211F19EE0766E2280A932Thu, 23 Jul 2026 03:07:03 GMTMarwan FakihMedical Oncology, Gastrointestinal Oncology, Colorectal cancer, Colorectal adenocarcinoma, Appendiceal cancer, Anal squamous cell carcinoma, Neuroendocrine carcinoma, Diabetes, Nivolumab, Ipilimumab, Pembrolizumab, Encorafenib, Cetuximab, Panitumumab, Bevacizumab, Capecitabine, Fluorouracil, Leucovorin, Floxuridine, Trifluridine, Tipiracil, Fruquintinib, Regorafenib, Tucatinib, Trastuzumab, Sotorasib, Adagrasib, ORCHESTRA, TRIBE, TRIBE2, TRIPLETE, DEEPER, AVEX, PANDA, EORTC 40983, JCOG0603, PUMP, Colon, Rectum, Liver, Lung, Peritoneum, Lymph nodes, Bone, Ovary, Brain, MSI-H, dMMR, MSS, pMMR, KRAS, NRAS, BRAF V600E, HER2, KRAS G12C, NTRK1, NTRK2, NTRK3, RET, ALK, ROS1, ctDNA, CEA, PD-L1, CT, MRI, Liver MRI, Pelvic MRI, Colonoscopy, Complete blood count, Comprehensive metabolic panel, Electrocardiogram, Surgery, Hepatic resection, Thermal ablation, Stereotactic body radiation therapy, Hepatic arterial infusion, Liver volumetry, Germline evaluation, Bowel obstruction, Perforation, Bleeding, Pain, Sepsis, Neuropathy, Diarrhea, Fatigue, Checkpoint inhibitor therapy, Immunotherapy, Chemotherapy, Oxaliplatin, Irinotecan, FOLFOX, FOLFIRI, CAPOX, FOLFOXIRI, mFOLFOX6, Supportive care, Palliative careAdjuvant Pembrolizumab in Renal Cell Carcinoma: Who Should Receive It?

This algorithm should answer one focused clinical question: After nephrectomy for high-risk RCC, which patients should receive adjuvant pembrolizumab and which patients should undergo active surveillance?
The goal is not to summarize all adjuvant RCC trials. The goal is to help clinicians make a practical post-nephrectomy decision.

]]>https://myopenmedicine.com/algorithms/adjuvant-pembrolizumab-in-renal-cell-carcinoma-who-should-receive-it/C8A1F88E4E3411F194D9766E2280A932https://myopenmedicine.com/algorithms/adjuvant-pembrolizumab-in-renal-cell-carcinoma-who-should-receive-it/C8A1F88E4E3411F194D9766E2280A932Thu, 23 Jul 2026 03:07:02 GMTNatalia GandurRenal cell carcinoma, Metastatic renal cell carcinoma, Papillary renal cell carcinoma, Chromophobe renal cell carcinoma, Collecting duct carcinoma, Medullary carcinoma, Autoimmune disease, Inflammatory bowel disease, Pneumonitis, Hepatitis, Pembrolizumab, KEYNOTE-564, Kidney, Chest, Abdomen, Pelvis, Brain, Computed tomography, Magnetic resonance imaging, Urinalysis, Complete blood count, Comprehensive metabolic panel, Creatinine, Estimated glomerular filtration rate, Nephrectomy, Resection, Active surveillance, Adjuvant pembrolizumab, Immunotherapy, Chronic immunosuppression, Immune-related adverse events, Immune-related toxicity, Oncology, Genitourinary oncologyComprehensive thoracic solid tumor staging and treatment optionsLung cancer management based on TNM staging, where early-stage (I–II) disease is primarily treated with surgical resection (with possible adjuvant therapy), while more advanced stages (III–IV) incorporate multimodal approaches including chemotherapy, radiation, and immunotherapy guided by resectability and molecular/PD-L1 status. Treatment decisions progressively shift from surgery-focused to systemic and combined therapies as stage and nodal/metastatic involvement increase.

]]>https://myopenmedicine.com/algorithms/comprehensive-thoracic-solid-tumor-staging-and-treatment-options/CD32B446376611F1A3AE766E2280A932https://myopenmedicine.com/algorithms/comprehensive-thoracic-solid-tumor-staging-and-treatment-options/CD32B446376611F1A3AE766E2280A932Thu, 23 Jul 2026 03:07:01 GMTAndrea BillèOncology, Thoracic oncology, Lung cancer, Osimertinib, Chest wall, Lung, PD-L1, EGFR, ALK, TNM staging, Surgical resection, Video-assisted thoracoscopic surgery, Robot-assisted thoracic surgery, Wedge resection, Segmentectomy, Lobectomy, Salvage surgery, Adjuvant therapy, Chemotherapy, Radiation therapy, ImmunotherapyInitial Treatment for Metastatic Pancreatic CancerInitial treatment for metastatic pancreatic cancer based on performance status and genetic testing.

]]>https://myopenmedicine.com/algorithms/initial-treatment-for-metastatic-pancreatic-cancer/D52FE4A8EDB311F08C3A766E2280A932https://myopenmedicine.com/algorithms/initial-treatment-for-metastatic-pancreatic-cancer/D52FE4A8EDB311F08C3A766E2280A932Thu, 23 Jul 2026 03:06:57 GMTMike J. PishvaianMetastatic pancreatic cancer, Pancreatic cancer, Capecitabine, Gemcitabine, Nab-paclitaxel, Cisplatin, Olaparib, Fluorouracil, Irinotecan, Oxaliplatin, BRCA1, BRCA2, PALB2, KRAS, Mismatch repair deficiency, Germline testing, Tumor molecular profiling, FOLFIRINOX, NALIRIFOXLow Risk and Favorable Intermediate Risk for Prostate CancerSelection and follow-up for men with low-risk and select favorable intermediate-risk prostate cancer. Tyler Seibert, MD, PhD, Genitourinary Section Chief at UC San Diego Radiation Oncology outlines criteria based on risk group, pathology features, and imaging, followed by a structured monitoring plan using PSA, MRI, and biopsy. The goal is to safely delay treatment while identifying progression early and transitioning to definitive therapy when needed.

]]>https://myopenmedicine.com/algorithms/low-risk-and-favorable-intermediate-risk-for-prostate-cancer/D9BC33DC248B11F1AE8D766E2280A932https://myopenmedicine.com/algorithms/low-risk-and-favorable-intermediate-risk-for-prostate-cancer/D9BC33DC248B11F1AE8D766E2280A932Thu, 23 Jul 2026 03:06:56 GMTTyler SeibertProstate cancer, Prostate, Prostate-specific antigen, Magnetic resonance imaging, Digital rectal examination, Biopsy, Targeted biopsy, Pathology review, Active surveillance, Radiation therapy, Radical prostatectomy, Androgen deprivation therapy, Cribriform pattern, Intraductal carcinomaFront-Line Treatment and Maintenance in Epithelial Ovarian CancerThe algorithm is broadly aligned with current frontline epithelial ovarian cancer practice: staging-based surgical approach (PDS vs NACT-IDS), platinum-taxane chemotherapy backbone, optional bevacizumab in appropriate advanced-stage patients, and biomarker-directed first-line maintenance using PARP inhibitors. The maintenance stratification by BRCA and HRD status reflects the pivotal trial evidence and major guideline recommendations. A key caveat is that PARP inhibitor benefit/risk in HRD-negative (and some HRD-unknown) populations has become more contentious due to overall survival signals and evolving regulatory/guideline language; local/regional approvals and updated guideline versions should be checked.

]]>https://myopenmedicine.com/algorithms/front-line-treatment-and-maintenance-in-epithelial-ovarian-cancer/12B764F36E9411F1AD30766E2280A932https://myopenmedicine.com/algorithms/front-line-treatment-and-maintenance-in-epithelial-ovarian-cancer/12B764F36E9411F1AD30766E2280A932Thu, 23 Jul 2026 03:07:20 GMTKathleen MooreEpithelial ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer, Bowel obstruction, Hypertension, Proteinuria, Anemia, Neutropenia, Thrombocytopenia, Myelodysplastic syndrome, Acute myeloid leukemia, Carboplatin, Paclitaxel, Bevacizumab, Olaparib, Niraparib, GOG-0218, ICON7, Fallopian tube, Peritoneum, Bowel, CA-125, BRCA1, BRCA2, HRD, MMR, MSI, HER2, NTRK, FRα, CT chest/abdomen/pelvis, Germline BRCA1/2 testing, Somatic tumor testing, CBC with differential, Platelet count, Renal function tests, Liver function tests, Surgical staging, Primary debulking surgery, Interval debulking surgery, Ascites, Neuropathy, Fatigue, Nausea, Abdominal pain, Neoadjuvant chemotherapy, Platinum-based chemotherapy, Maintenance therapyMultiple myeloma treatments at first relapse with bispecifics availableHow I think about treatments at first relapse, assuming bispecifics are available at 1st relapse.

]]>https://myopenmedicine.com/algorithms/multiple-myeloma-treatments-at-first-relapse-with-bispecifics-available/0FAB2981FE1111F0842F766E2280A932https://myopenmedicine.com/algorithms/multiple-myeloma-treatments-at-first-relapse-with-bispecifics-available/0FAB2981FE1111F0842F766E2280A932Thu, 23 Jul 2026 03:07:21 GMTManni MohyuddinHematology, Hematologic oncology, Multiple myeloma, Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Bispecific antibody therapy, CAR T-cell therapy, Stem cell collection, Stem cell transplant, Biochemical relapse, ObservationAMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in HRR-Altered mCSPCThe algorithm is broadly aligned with current mCSPC practice for diagnosis, early treatment intensification with AR pathway inhibitors, and routine consideration of germline/somatic testing. However, use of niraparib + abiraterone/prednisone + ADT specifically in mCSPC is not yet an established standard of care in most guidelines (as of recent public evidence), and is best framed as clinical-trial driven or dependent on local regulatory approval. The safety/monitoring and sequencing concepts are consistent with PARP inhibitor class use and prostate cancer care pathways.

]]>https://myopenmedicine.com/algorithms/amplitude-niraparib-abiraterone-prednisone-adt-in-hrr-altered-mcspc/E2D22D596EEF11F1AD30766E2280A932https://myopenmedicine.com/algorithms/amplitude-niraparib-abiraterone-prednisone-adt-in-hrr-altered-mcspc/E2D22D596EEF11F1AD30766E2280A932Tue, 23 Jun 2026 10:40:01 GMTNatalia Gandurprostate cancer, myelodysplastic syndrome, acute myeloid leukemia, niraparib, abiraterone acetate, prednisone, prednisolone, docetaxel, AMPLITUDE, bone, homologous recombination repair, BRCA1, BRCA2, circulating tumor DNA, cfDNA, copy-number loss, copy-number deletion, testosterone, prostate-specific antigen, PSA, germline testing, tumor tissue testing, PSMA PET, DEXA, complete blood count, CBC, platelet count, neutrophil count, liver function tests, renal function tests, potassium, bilateral orchiectomy, androgen deprivation therapy, ADT, radiotherapy, transfusion, pain, fatigue, nausea, edema, fever, bleeding, bruisingEarly-stage HER2+ breast cancerTreatment algorithm for early-stage (IIA, IIB, III) HER2+ breast cancer.  Reference diagram.


]]>https://myopenmedicine.com/algorithms/early-stage-her2-breast-cancer/E5659D7CDF6811F0991F766E2280A932https://myopenmedicine.com/algorithms/early-stage-her2-breast-cancer/E5659D7CDF6811F0991F766E2280A932Thu, 23 Jul 2026 03:06:50 GMTPaolo TarantinoBreast cancer, HER2, Hormone receptor, Pathologic complete response, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Trastuzumab deruxtecan, T-DXd, Ado-trastuzumab emtansine, T-DM1, Surgery, Lymph nodePharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)Published in Nature Article: Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)

McGowan, B., Ciudin, A., Baker, J.L. et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med 31, 3229–3232 (2025). https://doi.org/10.1038/s41591-025-03765-w

]]>https://myopenmedicine.com/algorithms/pharmacological-treatment-of-obesity-and-its-complications-from-the-european-association-for-the-study-of-obesity-easo/E8DF20CBEFED11F08C3A766E2280A932https://myopenmedicine.com/algorithms/pharmacological-treatment-of-obesity-and-its-complications-from-the-european-association-for-the-study-of-obesity-easo/E8DF20CBEFED11F08C3A766E2280A932Thu, 23 Jul 2026 03:06:49 GMTObesity, OSAS, Obstructive sleep apnea, KOA, Knee osteoarthritis, Prediabetes, Type 2 diabetes, CVD, Cardiovascular disease, Heart failure, MASLD, Metabolic dysfunction-associated steatotic liver disease, MASH, Metabolic dysfunction-associated steatohepatitis, Tirzepatide, Semaglutide, Liraglutide, Orlistat, Phentermine, Topiramate, Naltrexone, Bupropion, Pharmacological treatment, Body weight management, Obesity management, Complications management, Diabetes remission, Normoglycemia restoration, MASH remission, Fat mass accumulation, MACE, Hospitalization for heart failureManagement Algorithms for Relapsed/Refractory AL Amyloidosishttps://myopenmedicine.com/algorithms/management-algorithms-for-relapsed-refractory-al-amyloidosis/0E1DDE13069811F1842F766E2280A932https://myopenmedicine.com/algorithms/management-algorithms-for-relapsed-refractory-al-amyloidosis/0E1DDE13069811F1842F766E2280A932Tue, 10 Feb 2026 15:49:16 GMTRajshekhar ChakrabortyAL amyloidosis, daratumumab, bortezomib, cyclophosphamide, dexamethasone, pomalidomide, lenalidomide, autologous stem cell transplantation, t(11;14) translocationThymic epithelial tumors managementThymic epithelial tumors management framework by resectability. Resectability matrix.

]]>https://myopenmedicine.com/algorithms/thymic-epithelial-tumors-management/09DA4B97E04D11F0991F766E2280A932https://myopenmedicine.com/algorithms/thymic-epithelial-tumors-management/09DA4B97E04D11F0991F766E2280A932Thu, 23 Jul 2026 03:07:22 GMTJennifer MarksThymic epithelial tumor, Carboplatin, Paclitaxel, Ramucirumab, Cisplatin, Etoposide, Surgery, Induction chemotherapy, Induction chemoradiation, Systemic chemotherapy, Postoperative radiation therapyLocalized, borderline resectable and metastatic gastrointestinal stromal tumors (GISTs)This algorithm is broadly aligned with contemporary GIST management: upfront histologic diagnosis, mandatory KIT/PDGFRA molecular testing to guide systemic therapy, risk-adapted use of adjuvant imatinib after complete resection, and standard TKI sequencing for advanced disease (imatinib → sunitinib → regorafenib → ripretinib) with avapritinib for PDGFRA D842V. Neoadjuvant imatinib for borderline resectable disease with sensitive mutations and response-based timing of surgery is consistent with major guidelines, though evidence is largely nonrandomized. Surveillance intervals are generally consistent with guideline ranges but vary across societies and are often individualized.

]]>https://myopenmedicine.com/algorithms/localized-borderline-resectable-and-metastatic-gastrointestinal-stromal-tumors-gists/FE24B616560511F1AA64766E2280A932https://myopenmedicine.com/algorithms/localized-borderline-resectable-and-metastatic-gastrointestinal-stromal-tumors-gists/FE24B616560511F1AA64766E2280A932Thu, 23 Jul 2026 03:06:44 GMTMichael WagnerGastrointestinal stromal tumor, GIST, Sarcoma, Imatinib, Sunitinib, Regorafenib, Ripretinib, Avapritinib, Abdomen, Pelvis, KIT mutation, PDGFRA mutation, PDGFRA exon 18 D842V mutation, BRAF V600E, NF1, NTRK fusion, RAS pathway mutation, FGFR alteration, PIK3CA mutation, Histologic diagnosis, Mutation testing, Biopsy, CT, MRI, PET, Surgical resection, Re-biopsy, Neoadjuvant therapy, Adjuvant therapy, Surveillance, Dose escalation, Systemic therapy, Molecularly guided therapyBone health management in patients with prostate cancerThe algorithm is broadly aligned with contemporary guidance that men receiving ADT are at increased risk of bone loss and fracture and should undergo baseline fracture risk assessment with BMD (DEXA) where feasible, lifestyle/calcium/vitamin D optimization, and pharmacologic therapy for higher-risk patients. Use of antiresorptives (bisphosphonates or denosumab) is consistent with major osteoporosis/oncology guidance, and denosumab has direct RCT evidence for fracture reduction in men on ADT. Some regimen specifics (e.g., zoledronic acid dosing frequency with radium-223, thresholds such as ≥4%/year BMD loss, and fixed treatment durations/stop rules) are more institution- or osteoporosis-practice–derived and not uniformly standardized across major prostate-cancer guidelines.

FEBRUARY 2026 Clinical Oncology National guideline of bone health management in patients with prostate cancer.

]]>https://myopenmedicine.com/algorithms/bone-nbsp-health-management-in-nbsp-patients-with-prostate-cancer/225B3A9447DB11F194D9766E2280A932https://myopenmedicine.com/algorithms/bone-nbsp-health-management-in-nbsp-patients-with-prostate-cancer/225B3A9447DB11F194D9766E2280A932Thu, 23 Jul 2026 03:07:12 GMTAlison BirtleOncology, Genitourinary oncology, Prostate cancer, Osteoporosis, Fracture, Denosumab, Zoledronic acid, Alendronic acid, Risedronate sodium, Prednisolone, Lumbar spine, Total hip, Femoral neck, Vitamin D level, Bone mineral density, Dual-energy X-ray absorptiometry, Intravenous infusion, Subcutaneous injection, Bone pain, Lower back pain, Muscle pain, Muscle weakness, Androgen deprivation therapy, Calcium supplementation, Vitamin D supplementation, Radium-223Belzutifan Practical Guidance in Advanced Clear-Cell RCCThis belzutifan-focused pathway is broadly aligned with current evidence and labeling for advanced/metastatic ccRCC after prior PD-(L)1 inhibitor and VEGF-targeted therapy, centering on LITESPARK-005 and the WELIREG prescribing information. The algorithm appropriately emphasizes baseline and on-treatment monitoring for mechanism-related anemia and hypoxia and includes pragmatic dose interruption/reduction concepts. Its scope is appropriately narrow (monotherapy, later-line) and correctly defers broader sequencing to other pathways.

]]>https://myopenmedicine.com/algorithms/belzutifan-practical-guidance-in-advanced-clear-cell-rcc/4B1D931B78BC11F1AD30766E2280A932https://myopenmedicine.com/algorithms/belzutifan-practical-guidance-in-advanced-clear-cell-rcc/4B1D931B78BC11F1AD30766E2280A932Thu, 23 Jul 2026 03:07:37 GMTToni ChoueiriJames LarkinRenal cell carcinoma, Chronic obstructive pulmonary disease, Interstitial lung disease, Iron deficiency anemia, Vitamin B12 deficiency, Folate deficiency, Pulmonary embolism, Pneumonia, Pleural effusion, Belzutifan, Pembrolizumab, Tivozanib, Cabozantinib, Lenvatinib, Everolimus, Axitinib, LITESPARK-005, Kidney, Lung, Bone, Lymph node, Liver, Brain, Hemoglobin, Ferritin, Serum iron, Transferrin saturation, Total iron-binding capacity, Platelet count, Lymphocytes, Creatinine, Alanine aminotransferase, Aspartate aminotransferase, Complete blood count, Pulse oximeter, Oxygen saturation, Chest imaging, PaO2, RECIST, Nephrectomy, Monotherapy, Dose interruption, Dose reduction, Transfusion, Intravenous iron, Supplemental oxygen, Non-hormonal contraception, Anemia, Hypoxia, Dyspnea, Fatigue, Dizziness, Headache, Nausea, Rash, Hypertension, Musculoskeletal pain, Visual impairment, Hemorrhage, Pain, Weight loss, Appetite loss, Pulmonary evaluationFirst-Line Metastatic Urothelial Carcinoma: EV + Pembrolizumab vs Platinum-Based TherapyThis algorithm (1L Metastatic Urothelial Carcinoma: EV/Pembro vs Platinum) should answer one practical question: In a patient with previously untreated unresectable or metastatic urothelial carcinoma, should first-line therapy be EV + pembrolizumab or platinum-based chemotherapy?

The goal is not to recreate a full “Advanced Bladder Cancer” pathway. The goal is to define who should receive EV/pembrolizumab upfront, and when platinum-based chemotherapy followed by maintenance avelumab remains clinically relevant.

]]>https://myopenmedicine.com/algorithms/first-line-metastatic-urothelial-carcinoma-ev-pembrolizumab-vs-platinum-based-therapy/78F9EDD34A4511F194D9766E2280A932https://myopenmedicine.com/algorithms/first-line-metastatic-urothelial-carcinoma-ev-pembrolizumab-vs-platinum-based-therapy/78F9EDD34A4511F194D9766E2280A932Thu, 23 Jul 2026 03:07:30 GMTNatalia GandurMetastatic urothelial carcinoma, Bladder cancer, Enfortumab vedotin, Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine, Avelumab, Neuropathy, Hearing loss, Eastern Cooperative Oncology Group performance status, Estimated glomerular filtration rate, Creatinine clearance, FGFR2 alteration, FGFR3 alteration, Chemotherapy, Immunotherapy, Palliative care, Best supportive care, Bladder, UrethraTherapeutic Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC)https://myopenmedicine.com/algorithms/therapeutic-sequencing-in-metastatic-castration-resistantprostate-cancer-mcrpc/546355E44B0211F194D9766E2280A932https://myopenmedicine.com/algorithms/therapeutic-sequencing-in-metastatic-castration-resistantprostate-cancer-mcrpc/546355E44B0211F194D9766E2280A932Thu, 23 Jul 2026 03:07:35 GMTNeal ShoreMetastatic castration-resistant prostate cancer, Prostate cancer, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Docetaxel, Sipuleucel-T, Radium-223, Olaparib, Rucaparib, Pembrolizumab, Entrectinib, Larotrectinib, Cabazitaxel, Prednisone, Denosumab, Zoledronic acid, Bone, Vertebral bodies, Pelvis, Viscera, Prostate-specific antigen, PSA, Testosterone, BRCA1, BRCA2, ATM, PALB2, Microsatellite instability, MSI-H, Mismatch repair deficiency, dMMR, Tumor mutational burden, TMB-H, NTRK fusion, PSMA, Radiographic progression, Germline genetic testing, Pain, Androgen deprivation therapy, 177Lu-PSMA-617, Best supportive careEGFR-driven stage IV NSCLC treatment pathwaysTreatment algorithm for stage IV metastatic non–small cell lung cancer (NSCLC) when biomarker testing confirms EGFR mutation, then a biomarker specific approach is used. Treatment selection is guided by patient comorbidities, performance status, organ function, adverse-event profiles, and access considerations.

]]>https://myopenmedicine.com/algorithms/egfr-driven-stage-iv-nsclc-treatment-pathways/5BEF06490B9511F19387766E2280A932https://myopenmedicine.com/algorithms/egfr-driven-stage-iv-nsclc-treatment-pathways/5BEF06490B9511F19387766E2280A932Thu, 23 Jul 2026 03:07:34 GMTStephen Liunon-small cell lung cancer, metastatic cancer, osimertinib, afatinib, datopotamab, sunvozertinib, FLAURA, FLAURA 2, MARIPOSA, MARIPOSA 2, TROPION-Lung05, PAPILLON, lung, EGFR mutation, PD-L1, EGFR exon 19 deletion, EGFR L858R, EGFR exon 20 insertion, EGFR G719X, EGFR L861Q, EGFR S768I, next-generation sequencing, DNA sequencing, RNA sequencing, biomarker testing, targeted therapy, chemotherapy, carboplatin, pemetrexedRaised prolactin levels or HyperprolactinemiaThe algorithm is broadly aligned with contemporary hyperprolactinaemia care: confirm true elevation, exclude physiologic/secondary/drug causes (including macroprolactin), proceed to pituitary MRI when persistent, and treat symptomatic prolactinomas primarily with dopamine agonists (cabergoline preferred). It appropriately places transsphenoidal surgery as second-line for intolerance/resistance or urgent complications and includes reasonable follow-up and consideration of dopamine-agonist withdrawal after sustained remission. Overall, it reflects major Endocrine Society/Pituitary Society recommendations, though some thresholds and follow-up intervals may vary by guideline and local practice.

]]>https://myopenmedicine.com/algorithms/raised-prolactin-levels-or-hyperprolactinemia/7CFA13D5426511F1B6B6766E2280A932https://myopenmedicine.com/algorithms/raised-prolactin-levels-or-hyperprolactinemia/7CFA13D5426511F1B6B6766E2280A932Thu, 23 Jul 2026 03:07:27 GMTPartha KarEndocrinology, Pituitary endocrinology, Hyperprolactinemia, Prolactinoma, Hypothyroidism, Hypogonadism, Osteoporosis, Cabergoline, Bromocriptine, Metoclopramide, Pituitary magnetic resonance imaging, Transsphenoidal surgery, Prolactin, Thyroid-stimulating hormone, Beta-human chorionic gonadotropin, Macroprolactin, Pituitary gland, Pituitary stalk, Amenorrhea, Infertility, Erectile dysfunction, Galactorrhea, Visual compromise, Estrogen, Testosterone, Calcium, Vitamin D, BisphosphonatesSystemic Therapy Selection for Metastatic Pheochromocytoma and ParagangliomaThe algorithm is broadly aligned with contemporary management of metastatic PPGL by emphasizing symptom stabilization, careful selection between observation vs treatment, and use of functional imaging (MIBG/SSTR) and molecular features to guide therapy. It appropriately incorporates newer prospective evidence for TKIs (sunitinib, cabozantinib) and the emergence of belzutifan for PPGL, while maintaining established options (HSA 131I-MIBG, CVD, temozolomide) and prioritizing clinical trials. Key limitations are the still-sparse randomized data for many sequences and heterogeneity across genotypes/imaging phenotypes, meaning several branches remain supported mainly by phase II/retrospective evidence and consensus guidance.

]]>https://myopenmedicine.com/algorithms/systemic-therapy-selection-for-metastatic-pheochromocytoma-and-paraganglioma/29DE22DB6E3D11F1AD30766E2280A932https://myopenmedicine.com/algorithms/systemic-therapy-selection-for-metastatic-pheochromocytoma-and-paraganglioma/29DE22DB6E3D11F1AD30766E2280A932Thu, 23 Jul 2026 03:07:08 GMTMichael GloverMetastatic pheochromocytoma, Metastatic paraganglioma, multiple endocrine neoplasia type 2, Belzutifan, Cabozantinib, Cyclophosphamide, Dacarbazine, Selpercatinib, Sunitinib, Temozolomide, Vincristine, Bone marrow, AST, ALT, Bilirubin, Creatinine, Estimated glomerular filtration rate, Complete blood count, Plasma free metanephrines, Urine fractionated metanephrines, Catecholamines, RET, SDHx, SDHB, MGMT methylation, Hemoglobin, MIBG scan, DOTATATE scan, FDG PET, Molecular profiling, Germline testing, Somatic testing, Hypertension, Palpitations, Headache, Sweating, Constipation, Cardiomyopathy, Pain, Neuropathy, Dyspnea, Hypoxemia, Observation, Surveillance, Radiopharmaceutical therapy, CVD chemotherapy, Peptide receptor radionuclide therapy, Lutetium-177 dotatate, Iodine-131 metaiodobenzylguanidine, Catecholamine blockadeManaging radiation toxicity abdominal pain and crampingHow Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages abdominal pain and cramping after radiation therapy (RT). Originally posted on YouTube "Managing Toxicity from Radiotherapy to Upper GI Cancers (esophagus, pancreas, liver)" by Dr. Sanford. 

]]>https://myopenmedicine.com/algorithms/managing-radiation-toxicity-abdominal-pain-and-cramping/60487FB50B7111F19387766E2280A932https://myopenmedicine.com/algorithms/managing-radiation-toxicity-abdominal-pain-and-cramping/60487FB50B7111F19387766E2280A932Thu, 23 Jul 2026 03:07:33 GMTNina Sanfordradiation therapy, abdominal pain, abdominal cramping, esophagitis, cancer, esophagus, pancreas, liver, inflammation, spasm, ulcer, fibrosis, stricture, enzyme insufficiency, bloating, steatorrhea, weight loss, pain control, scope, Protonix, sucralfate, Carafate, Bentyl, dicyclomine, Creon, tramadol, NorcoManagement of Platinum-Sensitive Recurrent Ovarian CancerThe algorithm is broadly aligned with contemporary management of platinum-sensitive recurrent epithelial ovarian cancer: use of platinum-based combinations, consideration of secondary cytoreductive surgery in carefully selected first-relapse patients, and maintenance approaches after response. It appropriately emphasizes patient/prior-therapy factors and recognizes the evolving/limited evidence for some biomarker-directed non-platinum options in this setting. Key caveats are that PARP inhibitor maintenance indications have narrowed in many regions due to OS/benefit–risk updates, and immunotherapy in ovarian cancer remains limited outside specific biomarkers/histologies and clinical trials.

]]>https://myopenmedicine.com/algorithms/management-of-platinum-sensitive-recurrent-ovarian-cancer/3486939E6EA511F1AD30766E2280A932https://myopenmedicine.com/algorithms/management-of-platinum-sensitive-recurrent-ovarian-cancer/3486939E6EA511F1AD30766E2280A932Thu, 23 Jul 2026 03:07:25 GMTKathleen MooreGynecologic Oncology, Ovarian Cancer, Ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer, Therapy-related myelodysplastic syndrome, Acute myeloid leukemia, Interstitial lung disease, Pneumonitis, Carboplatin, Paclitaxel, Gemcitabine, Bevacizumab, Niraparib, Mirvetuximab soravtansine, Cyclophosphamide, Pembrolizumab, Trastuzumab deruxtecan, Fallopian tube, Peritoneum, BRCA, Homologous recombination deficiency, Folate receptor alpha, HER2, Microsatellite instability, Mismatch repair, NTRK, PD-L1, CA-125, Complete blood count, Platelet count, Liver function tests, Renal function tests, Electrolyte panel, Chest computed tomography, Ophthalmology examination, Imaging, Secondary cytoreductive surgery, Complete gross resection, Ascites, Neuropathy, Fatigue, Nausea, Blurred vision, Keratopathy, Dry eye, Photophobia, Eye pain, Cough, Dyspnea, Fever, Platinum-based chemotherapy, Maintenance therapy, PARP inhibitor maintenance, Bevacizumab maintenance, Biomarker-directed therapyCutaneous MelanomaCutaneous Melanoma treatment algorithm by Breslow thickness and stage.

]]>https://myopenmedicine.com/algorithms/cutaneous-melanoma/24077385EFE611F08C3A766E2280A932https://myopenmedicine.com/algorithms/cutaneous-melanoma/24077385EFE611F08C3A766E2280A932Thu, 23 Jul 2026 03:07:10 GMTJames LarkinSapna PatelCutaneous melanoma, Melanoma, pembrolizumab, nivolumab, ipilimumab, relatlimab, lifileucel, Skin, BRAF mutation, Ultrasound surveillance, Excision, Sentinel lymph node biopsy, Neoadjuvant therapy, Adjuvant therapy, Targeted therapy, Anti-PD-1 therapy, Systemic therapy, Tumor-infiltrating lymphocyte therapy, Nivolumab plus ipilimumab, Nivolumab plus relatlimab, Anti-PD-1 monotherapy, Breslow thickness, Sentinel lymph node burdenAdvanced Dedifferentiated Liposarcoma: Systemic Therapyhttps://myopenmedicine.com/algorithms/advanced-dedifferentiated-liposarcoma-systemic-therapy/33B67883561E11F1AA64766E2280A932https://myopenmedicine.com/algorithms/advanced-dedifferentiated-liposarcoma-systemic-therapy/33B67883561E11F1AA64766E2280A932Thu, 23 Jul 2026 03:07:35 GMTMichael WagnerDedifferentiated liposarcoma, Liposarcoma, Metastatic disease, Abemaciclib, Doxorubicin, Eribulin, Trabectedin, Gemcitabine, Docetaxel, Dacarbazine, Ifosfamide, SARCO41, Retroperitoneum, Extremity, Chest, Abdomen, Pelvis, MDM2 amplification, CDK4 amplification, RB1 status, Histology review, Pathology review, MRI, CT, Tumor board review, Core needle biopsy, Surgery, Ablation, Systemic therapy, Chemotherapy, Radiation, Immunotherapy, Diarrhea, Complete blood count, Liver function tests, NeutropeniaType 2 Diabetes Clinical PathwayGlobal HbA1c Conversion Reference

For a global audience, targets are often expressed in two different units:
Standard Percentage (%) | SI Units (mmol/mol) | Context
  • 6.5%    |    48 mmol/mol    |    Early diagnosis / Tight control
  • 7.0%    |    53 mmol/mol    |    Standard Global Target
  • 8.0%     |    64 mmol/mol    |    Frail / Elderly / High hypo risk

]]>https://myopenmedicine.com/algorithms/type-2-diabetes-clinical-pathway/D4A1AE6F3A7B11F1B6B6766E2280A932https://myopenmedicine.com/algorithms/type-2-diabetes-clinical-pathway/D4A1AE6F3A7B11F1B6B6766E2280A932Fri, 17 Apr 2026 16:38:15 GMTPartha Karmedical specialty, subspecialty, type 2 diabetes mellitus, T2DM, metformin, pioglitazone, kidney, HbA1c, fasting glucose, lifestyle intervention, diet, exercise, weight loss, basal insulin, dose titration, hypoglycaemiaDe-intensification of therapy for Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)https://myopenmedicine.com/algorithms/de-intensification-of-therapy-for-low-grade-non-muscle-invasive-bladder-cancer-lg-nmibc/D5E10356498411F194D9766E2280A932https://myopenmedicine.com/algorithms/de-intensification-of-therapy-for-low-grade-non-muscle-invasive-bladder-cancer-lg-nmibc/D5E10356498411F194D9766E2280A932Thu, 23 Jul 2026 03:06:56 GMTAshish KamatUrology, Urologic Oncology, Bladder cancer, NMIBC, Bladder, Flexible cystoscopy, Urine cytology, Transurethral resection of bladder tumor, Active surveillance, Fulguration, Laser ablationMetastatic Clear-Cell RCC After IO-Based First-Line Therapy: Choosing the Next TreatmentThis algorithm guides next-line systemic therapy selection for patients with metastatic clear-cell renal cell carcinoma (ccRCC) who progress after first-line IO/TKI or IO/IO therapy. The algorithm is not intended to duplicate first-line metastatic RCC treatment selection. 


It focuses on one practical sequencing question: After progression on IO-based first-line therapy, what should be the next treatment?

The key principle is that routine immunotherapy rechallenge should not be the default. EAU notes that sequencing ICI with atezolizumab in CONTACT-03 did not improve ORR, PFS, or OS over single-agent TKI, and that tivozanib plus nivolumab in TiNivo-2 did not improve outcomes over tivozanib alone.

]]>https://myopenmedicine.com/algorithms/metastatic-clear-cell-rcc-after-io-based-first-line-therapy-choosing-the-next-treatment/334AFBDA5A0E11F19804766E2280A932https://myopenmedicine.com/algorithms/metastatic-clear-cell-rcc-after-io-based-first-line-therapy-choosing-the-next-treatment/334AFBDA5A0E11F19804766E2280A932Thu, 23 Jul 2026 03:07:05 GMTNatalia Gandurmetastatic clear-cell renal cell carcinoma, renal cell carcinoma, brain metastases, liver metastases, bone metastases, atezolizumab, nivolumab, ipilimumab, cabozantinib, axitinib, tivozanib, lenvatinib, everolimus, belzutifan, CONTACT-03, TiNivo-2, Medical Oncology, Genitourinary Oncology, radiographic progression, clinical progression, ECOG performance status, immunotherapy rechallengeSurgery for thymic tumourStage-based management of thymic tumors, emphasizing complete surgical resection (via VATS/RATS or open thymectomy) for early stages, with increasing need for en bloc resection of involved structures as stage advances. For locally advanced or potentially unresectable disease, induction therapy is recommended to achieve resectability, while selected recurrent cases may still be considered for tailored surgical resection depending on site and extent.

]]>https://myopenmedicine.com/algorithms/surgery-for-thymic-tumour/DDAC7DF7383411F1A3AE766E2280A932https://myopenmedicine.com/algorithms/surgery-for-thymic-tumour/DDAC7DF7383411F1A3AE766E2280A932Thu, 23 Jul 2026 03:06:55 GMTAndrea BillèThymic tumor, Thymoma, Thymus, Lung, Pericardium, Phrenic nerve, Diaphragm, Pleura, Mediastinum, Video-assisted thoracoscopic surgery, Robotic-assisted thoracic surgery, Thymectomy, En bloc resection, Diaphragmatic plication, Vascular resection, Vascular reconstruction, Pleurectomy, Pneumonectomy, Induction therapyAdvanced Clear-Cell RCC After Prior PD-(L)1 Therapy: When to Use Belzutifan–Lenvatinib vs VEGFR-TKI Sequencing

This algorithm should help clinicians decide how to sequence systemic therapy for patients with unresectable locally advanced or metastatic clear-cell renal cell carcinoma after progression on prior anti–PD-(L)1 therapy.

The practical clinical question is not simply “can belzutifan be used?” but rather: In which post–PD-(L)1 advanced ccRCC patients should belzutifan–lenvatinib be considered instead of cabozantinib or another VEGFR-TKI-based strategy?

This should be a focused RCC sequencing algorithm, not a broad metastatic RCC pathway. It should specifically address the post–PD-(L)1 setting, where clinicians often need to choose among cabozantinib, belzutifan-containing therapy, other VEGFR-TKI strategies, clinical trial, or later-line belzutifan monotherapy when label criteria are met. Population and treatment-driving variables
Target population: Adults with unresectable locally advanced or metastatic renal cell carcinoma with clear-cell component who have progressed after prior anti–PD-(L)1 therapy.

]]>https://myopenmedicine.com/algorithms/advanced-clear-cell-rcc-after-prior-pd-l-1-therapy-when-to-use-belzutifan-lenvatinib-vs-vegfr-tki-sequencing/D3061AE65B8011F186E5766E2280A932https://myopenmedicine.com/algorithms/advanced-clear-cell-rcc-after-prior-pd-l-1-therapy-when-to-use-belzutifan-lenvatinib-vs-vegfr-tki-sequencing/D3061AE65B8011F186E5766E2280A932Thu, 23 Jul 2026 03:06:58 GMTNatalia Gandurrenal cell carcinoma, anemia, hypoxia, belzutifan, lenvatinib, cabozantinib, LITESPARK-011, kidney, liver, brain, anti–PD-(L)1 therapy, complete blood count, hemoglobin, oxygen saturation, dyspnea, fatigue, dizziness, syncope, blood pressure, proteinuria, renal function test, liver function test, diarrhea, appetite loss, weight loss, brain metastases, VEGFR tyrosine kinase inhibitor, monotherapy, systemic therapy, supportive careEarly and Advanced Triple Negative Breast Cancer (TNBC)Post ASCO, ESMO and SABCS 2025 TNBC algorithm. 

Radiation is indicated for some with early stage disease. Add Zometa for postmenopausal patients, q6 months for 2-3 years (Early stage).

*Keynote522 studied adjuvant pembro irrespective of RD vs pCR, no clear data about combination of pembro + capecitabine. Olaparib showed improvements in outcomes in BRCA carriers with RD. **No data about ADC sequencing, ~60 of patients in DESTINY-breast04 had HER2 low, HR- disease.

]]>https://myopenmedicine.com/algorithms/early-and-advanced-triple-negative-breast-cancer-tnbc/4D23CD5F005811F1842F766E2280A932https://myopenmedicine.com/algorithms/early-and-advanced-triple-negative-breast-cancer-tnbc/4D23CD5F005811F1842F766E2280A932Thu, 23 Jul 2026 03:07:36 GMTIlana SchlamTriple negative breast cancer, Breast cancer, Zoledronic acid, Pembrolizumab, Capecitabine, Olaparib, Talazoparib, Trastuzumab deruxtecan, Sacituzumab govitecan, KEYNOTE-522, CREATE-X, OLYMPIA, KEYNOTE-355, ASCENT-04, ASCENT-03, TROPION-Breast02, OLYMPIAD, EMBRACA, DESTINY-Breast04, ASCENT, Axilla, PD-L1, HER2, Hormone receptor, BRCA1, BRCA2, Axillary ultrasound, Radiation therapy, Surgery, Neoadjuvant chemotherapy, Adjuvant therapy, Pathologic complete response, Residual diseaseHR+ Early Breast Cancer

Post ASCO, ESMO and SABCS 2025 HR+ Early Breast Cancer treatment algorithm. 

Add Zometa for 2-3 years for postmenopausal early-stage disease.*Patients with 4+ Lymph nodes and/or large tumors excluded from RxPONDER /TailorX, consider chemotherapy.**Stage 2A if N1 or NO G3 or NO G2 + Ki67 >20%, high risk genomic score, 2B, 3.

]]>https://myopenmedicine.com/algorithms/hr-early-breast-cancer/DF139FB1006811F1842F766E2280A932https://myopenmedicine.com/algorithms/hr-early-breast-cancer/DF139FB1006811F1842F766E2280A932Thu, 23 Jul 2026 03:06:52 GMTIlana SchlamBreast cancer, Zoledronic acid, Abemaciclib, Ribociclib, Olaparib, Giradestrant, RxPONDER, TAILORx, monarchE, NATALEE, OlympiA, lidERA, Lymph node, Ki-67, BRCA, Recurrence score, Surgery, Endocrine therapy, Chemotherapy, Ovarian function suppression, Aromatase inhibitorManagement of Platinum-Resistant and Later-Line Ovarian Cancerhttps://myopenmedicine.com/algorithms/management-of-platinum-resistant-and-later-line-ovarian-cancer/E0E20E6C72C911F1AD30766E2280A932https://myopenmedicine.com/algorithms/management-of-platinum-resistant-and-later-line-ovarian-cancer/E0E20E6C72C911F1AD30766E2280A932Thu, 23 Jul 2026 03:06:51 GMTKathleen MooreOvarian cancer, Fallopian tube cancer, Primary peritoneal cancer, Mirvetuximab soravtansine, Paclitaxel, Bevacizumab, Pembrolizumab, Nab-paclitaxel, Relacorilant, Trastuzumab deruxtecan, Ovary, Fallopian tube, Peritoneum, Folate receptor alpha, PD-L1, HER2, Immunohistochemistry, Cyclin E1, CCNE1 amplification, Platinum re-treatment, Chemotherapy, Biomarker testingMGUS ManagementMGUS (Monoclonal Gammopathy of Undetermined Significance) is managed through active surveillance (watchful waiting) to detect potential progression to multiple myeloma or related disorders, rather than immediate treatment. It involves risk-stratified, lifelong monitoring of M-protein levels, free light chains (FLC), and blood counts, typically every 6–12 months.

]]>https://myopenmedicine.com/algorithms/mgus-management/E15C76291E3C11F1AE8D766E2280A932https://myopenmedicine.com/algorithms/mgus-management/E15C76291E3C11F1AE8D766E2280A932Thu, 23 Jul 2026 03:06:50 GMTVincent RajkumarHematology, Plasma cell disorders, Monoclonal gammopathy of undetermined significance, MGUS, Multiple myeloma, Plasma cell malignancy, M-protein, Free light chains, FLC, Blood count, Active surveillance, Watchful waiting, Risk stratification, Laboratory monitoringEarly Identification and Management of Patients with Rash on Apalutamidehttps://myopenmedicine.com/algorithms/early-identification-and-management-of-patients-with-rash-on-apalutamide/2E59EBF23CDD11F1B6B6766E2280A932https://myopenmedicine.com/algorithms/early-identification-and-management-of-patients-with-rash-on-apalutamide/2E59EBF23CDD11F1B6B6766E2280A932Thu, 23 Jul 2026 03:07:14 GMTAlison BirtleDrug reaction with eosinophilia and systemic symptoms, DRESS, Stevens-Johnson syndrome, SJS, Toxic epidermal necrolysis, TEN, Eczema, Apalutamide, Prednicarbate, Mometasone furoate, Methylprednisolone aceponate, Hydrocortisone butyrate, Polidocanol, Prednisone, Triamcinolone acetonide, Clobetasol propionate, Leukocyte count, Atypical lymphocytes, Eosinophilia, NCI-CTCAE, Blood tests, Rash, Itch, Topical corticosteroid, Oral antihistamine, Oral steroids, Emollients, Soap substitute, SunblockAdvanced or metastatic clear cell RCC select phase 3 clinical trials in the first- and second-line settingsSelected phase 3 clinical trials in progress in the first- and second-line settings for advanced or metastatic clear cell RCC patients. 

(A) Design of the MK-6482-012 trial (NCT04736706) in the first-line setting, looking at pembrolizumab/lenvatinib in two triplet combinations with either a quavonlimab co-formulation or belzutifan versus standard of care. 
(B) Design of the Alliance-A031704/PDIGREE trial (NCT03793166) in the first-line setting, looking at a risk-adapted approach after induction treatment withnivolumab/ipilimumab. 
(C) Design of the LITESPARK-011 trial (NCT04586231) in the second- and third-line settings or after neoadjuvant or adjuvanttreatment, including a combination of belzutifan/lenvatinib in comparison to cabozantinib as monotherapy. 
IMDC = International Metastatic RCC Database Consortium; KPS = Karnofsky performance score; R = randomization; RCC = renal cell carcinoma; CR = complete response; PD = progressive disease.
First and Second-line Treatments in Metastatic Renal Cell Carcinoma, European Urology, Volume 87, Issue 2, 2025, Pages 143-154, https://doi.org/10.1016/j.eururo.2024.10.019.

]]>https://myopenmedicine.com/algorithms/advanced-or-metastatic-clear-cell-rcc-select-phase-3-clinical-trials-in-the-first-and-second-line-settings/414E5F65FE1C11F0842F766E2280A932https://myopenmedicine.com/algorithms/advanced-or-metastatic-clear-cell-rcc-select-phase-3-clinical-trials-in-the-first-and-second-line-settings/414E5F65FE1C11F0842F766E2280A932Thu, 23 Jul 2026 03:07:39 GMTToni Choueirirenal cell carcinoma, RCC, pembrolizumab, lenvatinib, quavonlimab, belzutifan, nivolumab, ipilimumab, cabozantinib, sunitinib, MK-6482-012, Alliance-A031704/PDIGREE, LITESPARK-011, kidney, histology, cytology, PD(L)1, systemic therapy, induction treatment, neoadjuvant treatment, adjuvant treatment, disease progression, randomization, Karnofsky performance score, International Metastatic RCC Database Consortium risk scoreStage I Testicular Germ Cell Tumors After Orchiectomy: Surveillance, Adjuvant Therapy, and Risk-Adapted Follow-UpThis algorithm is broadly aligned with contemporary stage I testicular GCT management: confirm true clinical stage I with appropriate post-orchiectomy marker kinetics and imaging, then select surveillance vs limited adjuvant therapy based on histology and relapse risk. It appropriately favors surveillance for most stage I seminoma and uses LVI to risk-adapt stage I NSGCT, with adjuvant BEP x1 as a common relapse-reduction option. Follow-up recommendations are consistent with modern efforts to minimize radiation (MRI as an alternative to CT) and to avoid routine PET in surveillance.

]]>https://myopenmedicine.com/algorithms/stage-i-testicular-germ-cell-tumors-after-orchiectomy-nbsp-surveillance-adjuvant-therapy-and-risk-adapted-follow-up/4068D1167B7F11F19EE0766E2280A932https://myopenmedicine.com/algorithms/stage-i-testicular-germ-cell-tumors-after-orchiectomy-nbsp-surveillance-adjuvant-therapy-and-risk-adapted-follow-up/4068D1167B7F11F19EE0766E2280A932Thu, 23 Jul 2026 03:07:40 GMTNatalia GandurTesticular germ cell tumor, Seminoma, Nonseminomatous germ cell tumor, Embryonal carcinoma, Teratoma, Carboplatin, Bleomycin, Etoposide, Cisplatin, Testis, Contralateral testis, Rete testis, Spermatic cord, Retroperitoneum, Alpha-fetoprotein, AFP, Beta-human chorionic gonadotropin, beta-hCG, Lactate dehydrogenase, LDH, Computed tomography, Magnetic resonance imaging, Chest X-ray, FDG-PET/CT, Radical inguinal orchiectomy, Retroperitoneal lymph node dissection, Sperm banking, Surveillance, Radiotherapy, Adjuvant chemotherapy, Neuropathy, Hearing loss, Pulmonary symptoms, Testosterone deficiency symptomsBiomarker-Directed Therapy Across Lines in Ovarian Cancerhttps://myopenmedicine.com/algorithms/biomarker-directed-therapy-across-lines-in-ovarian-cancer/3C42D4F172D111F1AD30766E2280A932https://myopenmedicine.com/algorithms/biomarker-directed-therapy-across-lines-in-ovarian-cancer/3C42D4F172D111F1AD30766E2280A932Thu, 23 Jul 2026 03:07:38 GMTKathleen MooreOvarian cancer, Fallopian tube cancer, Primary peritoneal cancer, Mirvetuximab soravtansine, Trastuzumab deruxtecan, Ovary, Fallopian tube, Peritoneum, BRCA, Homologous recombination deficiency, Folate receptor alpha, HER2, Microsatellite instability, MSI-H, Mismatch repair deficiency, dMMR, Tumor mutational burden, TMB, NTRK fusion, Cyclin E1, CCNE1 amplification, Immunohistochemistry, Biomarker testing, Maintenance therapyMonoclonal gammopathy–associated peripheral neuropathy (MGNS)https://myopenmedicine.com/algorithms/monoclonal-gammopathy-associated-peripheral-neuropathy-mgns/EFF78DC4426E11F1B6B6766E2280A932https://myopenmedicine.com/algorithms/monoclonal-gammopathy-associated-peripheral-neuropathy-mgns/EFF78DC4426E11F1B6B6766E2280A932Mon, 27 Apr 2026 19:26:06 GMTManni MohyuddinMonoclonal gammopathy–associated peripheral neuropathy, Peripheral neuropathy, Amyloidosis, POEMS syndrome, Waldenström macroglobulinemia, Distal acquired demyelinating neuropathy, Immune globulin intravenous, Rituximab, M protein, Vascular endothelial growth factor, Plasma cell clone treatmentIBCG Risk Stratification Model for Intermediate-Risk NMIBCIntermediate-Risk Non–Muscle-Invasive Bladder Cancer (IR NMIBC) Risk Stratification Model by the International Bladder Cancer Group (IBCG).

]]>https://myopenmedicine.com/algorithms/ibcg-risk-stratification-model-for-nbsp-intermediate-risk-nmibc/F96FB506351C11F1A3AE766E2280A932https://myopenmedicine.com/algorithms/ibcg-risk-stratification-model-for-nbsp-intermediate-risk-nmibc/F96FB506351C11F1A3AE766E2280A932Thu, 23 Jul 2026 03:06:46 GMTAshish KamatNon–muscle-invasive bladder cancer, NMIBC, Active surveillance, Intravesical therapy, Adjuvant therapy, Risk stratification modelAdjuvant RCC After Nephrectomy: Risk, Surveillance, Pembrolizumab, and the Pembro/Belzutifan Decisionhttps://myopenmedicine.com/algorithms/adjuvant-rcc-after-nephrectomy-risk-surveillance-pembrolizumab-and-the-pembro-belzutifan-decision/FD50E1437AED11F1AD30766E2280A932https://myopenmedicine.com/algorithms/adjuvant-rcc-after-nephrectomy-risk-surveillance-pembrolizumab-and-the-pembro-belzutifan-decision/FD50E1437AED11F1AD30766E2280A932Thu, 23 Jul 2026 03:06:45 GMTToni ChoueiriJames LarkinRenal cell carcinoma, Clear cell renal cell carcinoma, Pembrolizumab, Belzutifan, KEYNOTE-564, LITESPARK-022, Kidney, Chest, Abdomen, Pelvis, Hemoglobin, Creatinine, Estimated glomerular filtration rate, Aspartate aminotransferase, Alanine aminotransferase, Bilirubin, Thyroid-stimulating hormone, Thyroxine, Glucose, Hemoglobin A1c, Ferritin, Serum iron, Transferrin saturation, Total iron-binding capacity, Magnetic resonance imaging, Cross-sectional imaging, Complete blood count, Chemistry panel, Comprehensive metabolic panel, Pregnancy test, Oxygen saturation, Nephrectomy, Metastasectomy, Biopsy, Fatigue, Dyspnea, Dizziness, Palpitations, Diarrhea, Cough, Rash, Headache, Abdominal pain, Jaundice, Surveillance, Adjuvant therapy, Immune checkpoint inhibitor therapy, Transfusion, Iron infusion, ContraceptionLocalized and metastatic clear cell renal cell carcinoma (ccRCC)https://myopenmedicine.com/algorithms/localized-and-metastatic-clear-cell-renal-cell-carcinoma-ccrcc/B7890FEF555511F1AA64766E2280A932https://myopenmedicine.com/algorithms/localized-and-metastatic-clear-cell-renal-cell-carcinoma-ccrcc/B7890FEF555511F1AA64766E2280A932Thu, 23 Jul 2026 03:06:28 GMTSumanta PalClear cell renal cell carcinoma, KEYNOTE-564, Pembrolizumab, Nivolumab, Ipilimumab, Cabozantinib, Metastasectomy, Stereotactic body radiotherapy, Cytoreductive nephrectomy, Observation, Aggressive disease, AsymptomaticPost-EV + Pembrolizumab Progression in Urothelial Carcinoma: Choosing the Next TreatmentThis algorithm is designed for one focused clinical problem: selecting the next systemic therapy for patients with locally advanced unresectable or metastatic urothelial carcinoma whose disease has progressed after first-line enfortumab vedotin plus pembrolizumab. 


EV + pembrolizumab is now the preferred first-line standard in major guidelines, but there is still no universally accepted post-EV/pembrolizumab standard; publicly accessible guideline and review sources converge on a practical framework centered on platinum chemotherapy for platinum-naïve and fit patients, biomarker-directed therapy for selected tumors, and early clinical-trial referral.

]]>https://myopenmedicine.com/algorithms/post-ev-pembrolizumab-progression-in-urothelial-carcinoma-choosing-the-next-treatment/039892704D5711F194D9766E2280A932https://myopenmedicine.com/algorithms/post-ev-pembrolizumab-progression-in-urothelial-carcinoma-choosing-the-next-treatment/039892704D5711F194D9766E2280A932Thu, 23 Jul 2026 03:06:40 GMTNatalia Gandururothelial carcinoma, enfortumab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin, erdafitinib, futibatinib, enfortumab deruxtecan, trastuzumab deruxtecan, liver, FGFR2 alteration, FGFR3 alteration, HER2, radiographic assessment, neoadjuvant therapy, adjuvant therapy, neuropathy, hearing loss, platinum rechallenge, best supportive care, palliative interventionsHER2+ Breast CancerHER2+ Breast Cancer treatment algorithm updated with the latest from ASCO, ESMO and SABCS 2025 data.

]]>https://myopenmedicine.com/algorithms/her2-breast-cancer/8B55A83BFE2F11F0842F766E2280A932https://myopenmedicine.com/algorithms/her2-breast-cancer/8B55A83BFE2F11F0842F766E2280A932Thu, 23 Jul 2026 03:06:38 GMTIlana SchlamBreast cancer, Trastuzumab, Pertuzumab, Neratinib, Tucatinib, Capecitabine, Lapatinib, Margetuximab, Ado-trastuzumab emtansine, Trastuzumab deruxtecan, APT, APHINITY, NeoSphere, TRYPHAENA, KATHERINE, ExteNET, CLEOPATRA, DESTINY-Breast 03, DESTINY-Breast 12, HER2CLIMB, EMILIA, NALA, SOPHIA, Central nervous system, HER2, Surgery, Lymph node status, Neoadjuvant chemotherapy, Adjuvant chemotherapy, Endocrine therapy, Maintenance therapy, Pathologic complete response, Residual diseaseMGUS Diagnostic AlgorithmMonoclonal Gammopathy of Undetermined Significance (MGUS) is diagnosed via blood and urine tests that detect abnormal M-proteins, typically identified during routine checkups. It is defined by a serum M-protein level < 3 g/dL, < 10% plasma cells in the bone marrow, and an absence of end-organ damage (no bone lesions, anemia, or kidney failure).

]]>https://myopenmedicine.com/algorithms/mgus-diagnostic-algorithm/96F9D6DD1E3D11F1AE8D766E2280A932https://myopenmedicine.com/algorithms/mgus-diagnostic-algorithm/96F9D6DD1E3D11F1AE8D766E2280A932Thu, 23 Jul 2026 03:06:37 GMTVincent RajkumarHematology, Plasma cell disorders, Monoclonal gammopathy of undetermined significance, MGUS, Multiple myeloma, Smoldering multiple myeloma, SMM, Anemia, Kidney failure, Bone marrow biopsy, Blood test, Urine test, Bone imaging, M protein, Serum M protein, IgM, Free light chain ratio, Bone marrow, Bone lesionsManagement of 1st Relapse Multiple Myelomahttps://myopenmedicine.com/algorithms/management-of-1st-relapse-multiple-myeloma/83475EF767DA11F186E5766E2280A932https://myopenmedicine.com/algorithms/management-of-1st-relapse-multiple-myeloma/83475EF767DA11F186E5766E2280A932Thu, 23 Jul 2026 03:06:41 GMTRajshekhar ChakrabortyMultiple myeloma, Lenalidomide, Teclistamab, Daratumumab, Ciltacabtagene autoleucel, Talquetamab, Pomalidomide, Belantamab mafodotin, Bortezomib, Dexamethasone, Carfilzomib, Isatuximab, Mezigdomide, MajesTEC-3, CARTITUDE-4, MonumenTAL-3, DREAMM-7, DREAMM-8, CANDOR, IKEMA, MajesTEC-9, SUCCESSOR-2, CAR T-cell therapyMolecular Testing for Pancreatic CancerMolecular testing for pancreatic cancer at first visit and within the first 2-4 weeks.

]]>https://myopenmedicine.com/algorithms/molecular-testing-for-pancreatic-cancer/9987699AEDB411F08C3A766E2280A932https://myopenmedicine.com/algorithms/molecular-testing-for-pancreatic-cancer/9987699AEDB411F08C3A766E2280A932Fri, 9 Jan 2026 23:40:37 GMTMike J. PishvaianHigh Risk Prostate CancerBased on NCCN risk groups, Tyler Seibert, MD, PhD, Genitourinary Section Chief, UC San Diego Radiation Oncology outlines his general recommendations for patients with high risk prostate cancer (HR PCa).

]]>https://myopenmedicine.com/algorithms/high-risk-prostate-cancer/7FA056182C8611F1A062766E2280A932https://myopenmedicine.com/algorithms/high-risk-prostate-cancer/7FA056182C8611F1A062766E2280A932Thu, 23 Jul 2026 03:07:26 GMTTyler SeibertProstate cancer, NCCN risk groups, PSA, Prostate, Gleason grade group, Active surveillance, Radiation therapy, Androgen deprivation therapy, Radical prostatectomy, SurveillanceLung Cancer Surgery Post Chemo/IOSurgical decision making following chemoimmunotherapy for lung cancer, stratifying patients by tumor size, nodal status (N1 vs N2), and extent of invasion (e.g., T4). From minimally invasive lobectomy (VATS/RATS) to complex resections with vascular or chest wall involvement while emphasizing anatomical resection with appropriate lymph node dissection.

]]>https://myopenmedicine.com/algorithms/lung-cancer-surgery-post-chemo-io/A35A326D383711F1A3AE766E2280A932https://myopenmedicine.com/algorithms/lung-cancer-surgery-post-chemo-io/A35A326D383711F1A3AE766E2280A932Thu, 23 Jul 2026 03:06:33 GMTAndrea BillèThoracic surgery, Thoracic surgical oncology, Lung cancer, Tumor size, Nodal status, N1, N2, T4, Video-assisted thoracoscopic surgery, VATS, Robot-assisted thoracic surgery, RATS, Lobectomy, Bronchial sleeve resection, Arterial sleeve resection, Pneumonectomy, Hilar lymph node, Mediastinal lymph node dissection, Lymph node dissection, Laminectomy, Subclavian vessels resection, Subclavian vessels, Superior vena cava resection, Superior vena cava, Chest wall resection, Chest wall reconstruction, Chest wall, Mediastinal fat tissue resection, Mediastinal fat tissue, ChemoimmunotherapyPSMAfore: Taxane-naive PSMA-positive mCRPC after one prior ARPI progressionhttps://myopenmedicine.com/algorithms/psmafore-taxane-naive-psma-positive-mcrpc-after-one-prior-arpi-progression/A6C26B9E4B1D11F194D9766E2280A932https://myopenmedicine.com/algorithms/psmafore-taxane-naive-psma-positive-mcrpc-after-one-prior-arpi-progression/A6C26B9E4B1D11F194D9766E2280A932Thu, 23 Jul 2026 03:06:31 GMTKarim FizaziNeal ShoreMetastatic castration-resistant prostate cancer, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Sipuleucel-T, Lutetium (177Lu) vipivotide tetraxetan, PSMAfore, Prostate, Prostate-specific membrane antigen, Gallium Ga 68 gozetotide PET/CT, Taxane chemotherapy, Hemibody radiotherapy, Androgen deprivation therapyVery High Risk Prostate CancerBased on NCCN risk groups, Tyler Seibert, MD, PhD, Genitourinary Section Chief, UC San Diego Radiation Oncology outlines his general recommendations for patients with very high risk prostate cancer (PCa).

]]>https://myopenmedicine.com/algorithms/very-high-risk-prostate-cancer/B3AE6CB12C7E11F1A062766E2280A932https://myopenmedicine.com/algorithms/very-high-risk-prostate-cancer/B3AE6CB12C7E11F1A062766E2280A932Thu, 23 Jul 2026 03:06:30 GMTTyler SeibertProstate cancer, PCa, Abiraterone, Androgen deprivation therapy, Radiation therapy, Pelvic lymph nodes, Decipher, Elective pelvic nodal irradiation, NCCN risk groupsADT bone health management in prostate cancerhttps://myopenmedicine.com/algorithms/adt-bone-health-management-in-prostate-cancer/7A756A2D498111F194D9766E2280A932https://myopenmedicine.com/algorithms/adt-bone-health-management-in-prostate-cancer/7A756A2D498111F194D9766E2280A932Thu, 23 Jul 2026 03:07:28 GMTFred SaadUrology, Urologic oncology, Prostate cancer, Osteoporosis, Bone metastases, Fragility fracture, Denosumab, Zoledronic acid, Alendronate, Risedronate, Calcium, Vitamin D, Bone mineral density assessment, Dual-energy X-ray absorptiometry, FRAX, CAROC, BMD T-score, Androgen deprivation therapy, Bone targeted therapy, Subcutaneous injection, Intravenous infusionThoracic solid tumour resectability in the ERA of ImmunotherapyResectability Matrix in the ERA of Immunotherapy

There is no consensus reached for some stage features. Resectability decision making is key for patient to be eligible for chemo Immunotherapy. There are guidelines but there is no algorithm to help tumour board or surgeons to define resectability in N2 category or locally advanced cancer (T3 / T4).

]]>https://myopenmedicine.com/algorithms/thoracic-solid-tumour-resectability-in-the-era-of-immunotherapy/130D3107EFEB11F08C3A766E2280A932https://myopenmedicine.com/algorithms/thoracic-solid-tumour-resectability-in-the-era-of-immunotherapy/130D3107EFEB11F08C3A766E2280A932Mon, 12 Jan 2026 19:15:36 GMTAndrea BillèOncology, Thoracic oncology, Cancer, Thorax, Lymph node, Bronchus, Lung, Resectability, Lobectomy, Bilobectomy, Pneumonectomy, Neoadjuvant chemotherapy, Immunotherapy, Chemoradiotherapy, Surgery, Perioperative immunotherapy, Adjuvant therapyCentral nervous system (CNS) multiple myelomaCNS myeloma (CNS-MM) is when cancerous plasma cells infiltrate the central nervous system, which is normally protected by the blood–brain barrier. Ben Derman, MD Assistant Professor at University of Chicago offers his guidance on this rare and difficult to manage disease. Originally posted on X.

]]>https://myopenmedicine.com/algorithms/central-nervous-system-cns-multiple-myeloma/B8103312216C11F1AE8D766E2280A932https://myopenmedicine.com/algorithms/central-nervous-system-cns-multiple-myeloma/B8103312216C11F1AE8D766E2280A932Thu, 23 Jul 2026 03:06:27 GMTmultiple myeloma, central nervous system multiple myeloma, pomalidomide, lenalidomide, thalidomide, venetoclax, methotrexate, cytarabine, thiotepa, central nervous system, blood–brain barrier, plasma cells, leptomeninges, cranial nerve, cerebrospinal fluid, magnetic resonance imaging, flow cytometry, cytopathology, immunophenotyping, lumbar puncture, biopsy, confusion, headache, visual symptoms, weakness, cranial nerve palsies, intrathecal therapy, radiation therapy, BCMA CAR T-cell therapy, palliative careResectable NSCLCTreatment algorithm for resectable NSCLC. Resectability matrix.

]]>https://myopenmedicine.com/algorithms/resectable-nsclc/250ECB24ED9211F08C3A766E2280A932https://myopenmedicine.com/algorithms/resectable-nsclc/250ECB24ED9211F08C3A766E2280A932Thu, 23 Jul 2026 03:07:09 GMTJennifer MarksNon-small cell lung cancer, NSCLC, Nivolumab, Pembrolizumab, Durvalumab, Osimertinib, Alectinib, Surgery, Neoadjuvant therapy, Adjuvant therapy, Perioperative therapy, Chemotherapy, Immunotherapy, Tyrosine kinase inhibitorMetastatic Castration-Resistant Prostate Cancer After Prior ARPI: Choosing the Next TreatmentThis algorithm guides next-line systemic treatment selection in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior exposure to an androgen receptor pathway inhibitor (ARPI), including abiraterone, enzalutamide, apalutamide, or darolutamide.


The goal is to avoid a broad mCRPC overview and focus specifically on the practical sequencing question: After prior ARPI progression, what should be the next treatment?

]]>https://myopenmedicine.com/algorithms/metastatic-castration-resistant-prostate-cancer-after-prior-arpi-choosing-the-next-treatment/BDFB541E4A5011F194D9766E2280A932https://myopenmedicine.com/algorithms/metastatic-castration-resistant-prostate-cancer-after-prior-arpi-choosing-the-next-treatment/BDFB541E4A5011F194D9766E2280A932Thu, 23 Jul 2026 03:06:25 GMTNatalia Gandurmetastatic castration-resistant prostate cancer, prostate cancer, metastatic hormone-sensitive prostate cancer, nonmetastatic castration-resistant prostate cancer, abiraterone, enzalutamide, apalutamide, darolutamide, pembrolizumab, docetaxel, cabazitaxel, PSMAfore, CARD, VISION, TheraP, liver, testosterone, prostate-specific antigen, PSA, BRCA1, BRCA2, PALB2, CDK12, ATM, CHEK2, microsatellite instability-high, MSI-H, mismatch repair deficiency, dMMR, tumor mutational burden-high, TMB-high, prostate-specific membrane antigen, PSMA, lactate dehydrogenase, LDH, PSMA PET, biopsy, neuropathy, androgen deprivation therapy, PARP inhibitor, platinum-based chemotherapy, palliative radiation, best supportive care, Lu-177–PSMA, bone-directed therapyBCG-Unresponsive NMIBC: Radical Cystectomy vs Bladder-Sparing TherapyIn a patient with high-risk BCG-unresponsive NMIBC, who should proceed to early radical cystectomy and who is a reasonable candidate for bladder-sparing therapy?


This should not be a broad NMIBC algorithm. It should begin only after the clinician has already confirmed that the patient has high-risk NMIBC after adequate BCG exposure and now needs a definitive post-BCG decision.

]]>https://myopenmedicine.com/algorithms/bcg-unresponsive-nmibc-radical-cystectomy-vs-bladder-sparing-therapy/1CC41B355A3011F19804766E2280A932https://myopenmedicine.com/algorithms/bcg-unresponsive-nmibc-radical-cystectomy-vs-bladder-sparing-therapy/1CC41B355A3011F19804766E2280A932Thu, 23 Jul 2026 03:07:17 GMTNatalia GandurUrology, Urologic Oncology, non–muscle-invasive bladder cancer, NMIBC, urothelial carcinoma, muscle-invasive bladder cancer, MIBC, metastasis, carcinoma in situ, CIS, Bacillus Calmette-Guérin, BCG, pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept, gemcitabine, docetaxel, bladder, prostatic urethra, upper urinary tract, pathology review, imaging, cystoscopy, urine cytology, biopsy, radical cystectomy, transurethral resection of bladder tumor, TURBT, bladder-sparing therapy, intravesical chemotherapy, intravesical therapy, lymphovascular invasion, variant histologyManagement of Immune-Related Adverse Events (irAEs) in Patients Treated With Immune Checkpoint Inhibitor Therapyhttps://myopenmedicine.com/algorithms/management-of-immune-related-adverse-events-iraes-in-patients-treated-with-immune-checkpoint-inhibitor-therapy/62E971454B3211F194D9766E2280A932https://myopenmedicine.com/algorithms/management-of-immune-related-adverse-events-iraes-in-patients-treated-with-immune-checkpoint-inhibitor-therapy/62E971454B3211F194D9766E2280A932Thu, 23 Jul 2026 03:07:31 GMTMedical Oncology, Immuno-oncology, Immune-related adverse event, Common Terminology Criteria for Adverse Events, Diagnostic workup, Immune checkpoint inhibitor therapy, Prednisone, Methylprednisolone, Infliximab, Vedolizumab, Mycophenolate, Colitis, Hepatitis, Hormone replacement, Immunosuppression, Corticosteroid therapy, HospitalizationUniversal Germline Genetic Testing in Prostate Cancerhttps://myopenmedicine.com/algorithms/universal-germline-genetic-testing-in-prostate-cancer/C487D90F4A6711F194D9766E2280A932https://myopenmedicine.com/algorithms/universal-germline-genetic-testing-in-prostate-cancer/C487D90F4A6711F194D9766E2280A932Thu, 23 Jul 2026 03:06:20 GMTNeal ShoreProstate cancer, Breast cancer, Pancreatic cancer, Ovarian cancer, Colorectal cancer, Endometrial cancer, Urothelial cancer, Lynch syndrome, Prostate, Germline genetic testing, Pretest counseling, Multigene hereditary cancer panel, Tumor testing, Somatic testing, Active surveillance, Androgen-deprivation therapy, Immunotherapy, PARP inhibitor, BRCA2, BRCA1, ATM, CHEK2, PALB2, MSH2, MLH1, MSH6, DNA damage repair, Mismatch repair, Pathogenic germline variant, Likely pathogenic variant, Variant of uncertain significance, Homologous recombination repair, Cascade testingUnfavorable Intermediate Risk Prostate CancerBased on NCCN risk groups, Tyler Seibert, MD, PhD, Genitourinary Section Chief, UC San Diego Radiation Oncology outlines his general recommendations for patients with unfavorable intermediate risk prostate cancer (UIC PCa).

]]>https://myopenmedicine.com/algorithms/unfavorable-intermediate-risk-prostate-cancer/C55B9CCE2C7F11F1A062766E2280A932https://myopenmedicine.com/algorithms/unfavorable-intermediate-risk-prostate-cancer/C55B9CCE2C7F11F1A062766E2280A932Thu, 23 Jul 2026 03:06:32 GMTTyler SeibertProstate cancer, Relugolix, Leuprolide, Prostate, National Comprehensive Cancer Network, Decipher, Radiation therapy, Radical prostatectomy, Androgen deprivation therapyFirst line Metastatic Castration-Resistant Prostate Cancer (mCRPC)https://myopenmedicine.com/algorithms/first-line-metastatic-castration-resistant-prostate-cancer-mcrpc/61FCD5CB497F11F194D9766E2280A932https://myopenmedicine.com/algorithms/first-line-metastatic-castration-resistant-prostate-cancer-mcrpc/61FCD5CB497F11F194D9766E2280A932Wed, 6 May 2026 19:11:28 GMTFred SaadProstate cancer, Castration-resistant prostate cancer, mCRPC, Docetaxel, Radium-223, Cabazitaxel, Lutetium Lu 177 vipivotide tetraxetan, Abiraterone, Enzalutamide, Niraparib, Olaparib, Talazoparib, Viscera, HRR mutation, PSMA expression, Symptomatic, Androgen deprivation therapyNewly Diagnosed Philadelphia Chromosome–Positive ALL: Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Makinghttps://myopenmedicine.com/algorithms/newly-diagnosed-philadelphia-chromosome-positive-all-frontline-tki-selection-early-blinatumomab-mrd-and-allo-hct-decision-making/D1C09D5F7D6B11F19EE0766E2280A932https://myopenmedicine.com/algorithms/newly-diagnosed-philadelphia-chromosome-positive-all-frontline-tki-selection-early-blinatumomab-mrd-and-allo-hct-decision-making/D1C09D5F7D6B11F19EE0766E2280A932Thu, 23 Jul 2026 03:07:00 GMTTalha BadarAcute lymphoblastic leukemia, Chronic myeloid leukemia, Blinatumomab, Ponatinib, Dasatinib, Asciminib, D-ALBA, Central nervous system, Bone marrow, BCR::ABL1, T315I, IKZF1, CD19, CD22, Flow cytometry, Fluorescence in situ hybridization, Cytogenetics, Polymerase chain reaction, Next-generation sequencing, Lumbar puncture, Allogeneic hematopoietic cell transplantation, Leukostasis, Central nervous system prophylaxis, Chimeric antigen receptor T-cell therapy, Chemotherapy, Cytoreduction, Steroid prephase